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INTRODUCTION 
Since the early 1900s, in organized pari-mutuel horse racing, some form of drug 
testing has been necessary to insure that the industry is operating "drug-free", and all 
horses have equal opportunity to win races and resultant purses. In the early part of 
this century, the temptation to "dope" a horse was extensive. In fact, the practice of 
doping was widespread due to the inadequate detection techniques available at the 
time. These inadequacies allowed some trainers to perform criminal acts (doping), 
while those trainers who did obey the rules were put at a severe disadvantage. In one 
of the earliest reported instances of doping around the tum of the century, horses were 
d escribed as winning races with their eyes popping out of their heads, sweating 
profusely, and running as if possessed by the devil. One horse reportedly killed itself 
by running into a stone wall following a race. Testing of horses for drug presence by 
chemical analyses of bodily fluids was first introduced in Europe in 1910. In the first 
reported "positive", Bourba Rose was disqualified after winning France's golden cup in 
1912 (Tobin, 1981 ). 
As the years progressed, the ability of the chemist to analyze and detect various 
drugs and substances within the animal progressed to the point at which we are today. 
Using today's technology, chemists have the ability to d etect an enormous number of 
drugs at extremely minute concentrations in biological fluids. Chemical analysis of 
biological samples, usually urine and plasma, is a three step process: extraction of 
exogenous agent from the biological sample; followed by screening of the sample for 
any suspected agents; and legal confirmation of the agent's identify within the sample. 
Currently there are three commonly used screening procedures: 1) classical liquid-
liquid extraction followed by thin-layer chromatography and visualization of the plate, 
2) liquid-liquid extraction followed by high-performance liquid chromatography 
(HPLC) with ultraviolet absorption or gas chromatography with flame ionization or 
nitrogen selectivity, or 3) the newly developed immunoassay methodology such as 
radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and particle 
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concentration fluorescence immunoassay (PCFIA). Gas chromatography /mass 
spectrometry is the methodology commonly utilized to legally confirm analyte 
presence within a sample, regardless of the screening procedure used. 
The purpose of the study was to determine the relative merits among several 
immunochemical techniques, and to compare the relative sensitivity of classical 
detection to immunoassay and instrumental methods in the screening and 
confirmation of the narcotic analgesic fentanyl in equine urine and plasma. 
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LITERATURE REVIEW 
General Review of Fentanyl 
Characteristics in man 
Fentanyl, 1-(2-phenethyl)-4-N-(N-propionyl-anilino) piperidine, is an extremely 
potent synthetic narcotic analgesic with a very rapid onset of action. In man the major 
action is analgesia associated with euphoria and respiratory depression. Higher doses 
can produce muscle rigidity. Fentanyl is a 4-anilino-piperidine derivative of 
meperidine. First manufactured by Janssen in 1960, fentanyl was found to ha ve 
pharmacological actions similar to morphine, and was approximately 400 times more 
potent as an opioid agonist in the tail-withdrawal reflex reaction of rats (Janssen et al., 
1963). The citrate salt of fentanyl, fentanyl citrate, N-{1-phenethyl-4-piperidyl) 
propionanilide, commercially known as Sublimaze®, was also derived from 
meperidine and was first synthesized by Janssen in 1959 (Janssen et al., 1963; Janssen, 
1964). 
In man, fentanyl has been used since the early 1960s for the relief of pain and pre-
opera tive anesthesia (Holderness et fil., 1963; Dobkin and Su, 1966). Fentanyl has 
enjoyed widely accepted use due to a very fast onset and short duration of action, and a 
potency clinically estimated at approximately 150 times that of morphine (Janssen et 
fil., 1963; Shephard, 1965; Finch and DeKomfeld, 1967; Grell et al., 1970; Hess et al., 1972; 
Martin, 1984; Jaffe and Martin, 1985). One of the major drawbacks of fentanyl is that 
high doses may cause severe respiratory depression either initially, or several hours 
after administration (Downes et fil., 1967; Finch and DeKornfeld, 1967; Grell et al., 1970; 
Anderson et al., 1976; Becker et fil., 1976; Harper et al., 1976; Adams and Pybus, 1978; 
McQuay et al., 1979; Stoeckel et al., 1979; Klausner et al., 1988). Fentanyl was implicated 
in the overdose deaths of several individuals in the United States who gave 
themselves very large intravenous injections, apparently dying from extreme 
respiratory depression (Garriott et fil., 1984; Pare et al., 1987). 
4 
Characteristics in equine 
As previously mentioned, in man the major action of fentanyl is analgesia, with 
euphoria and respiratory depression. When administered to the horse, however, a 
wide variety of effects occur including respiratory depression, analgesia, increased 
cardiac and respiratory rates, and most importantly stimulation of the central nervous 
system. Instead of sedating the horse, when administered at low levels fentanyl 
stimulated the horse to a brisk trot, while at the same time alleviating any lameness 
(Combie, 1979; Combie et al., 1979; Tobin et al., 1979a; Tobin et al., 1979b; Tobin, 1981; 
Kamerling et al., 1985). 
The fact that fentanyl can stimulate the locomotor activity of the horse is of extreme 
importance to the pari-mutuel horse racing industry. Trainers may give their animal 
an injection of fentanyl hoping to gain an unfair advantage, leaving trainers who obey 
the rules at a disadvantage because they do not resort to criminal tactics. 
Almost all racing jurisdictions in the United States have rules prohibiting the use of 
fentanyl in the racing equine. As previously mentioned, fentanyl is classified as a 
narcotic analgesic, and all narcotic analgesics stimulate the central nervous system of 
the equine. The classification of fentanyl, however, was not always as a stimulant 
within the horse. In 1977 the "California Rules of Racing" listed fentanyl as a 
depressant on its list of prohibited drugs. This classification dramatically changed in 
1979, as Tobin demonstrated that a small dose of fentanyl stimulates the locomotor 
response in the horse upon administration (Tobin et al., 1979a; Tobin et al., 1979b). 
Tobin et al. (1979b) developed a method to quantitate the presence of fentanyl in the 
horse. The method involved counting the number of times the animal lifted its left 
front foreleg every two minute period. It was reported that a dose of 2.0 µg/kg was 
being used in the racing industry to dope a horse. However, when this dosage was 
injected intravenously, no observable effects were noticed (Tobin et fil., 1979b). A dose 
between 10.0 µg/ kg and 20.0 µg/ kg produced an effect that peaked at about 110 steps / 2 
minute period and then declined to control values at 60 minutes. When the dosage 
was increased to 40.0 µg / kg the horse became uncoordinated, staggered, and sometimes 
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fell within the first few minutes. The intensity of the trotting response was directly 
proportional to the level of fentanyl injected intravenously into the horse (Tobin et .fil., 
1979b; Combie et al., 1979). 
The maximum locomotor activity of fentanyl occurred at approximately five 
minutes following intravenous administration, corresponding to a concentration of 50 
ng / ml in the blood stream (Combie, 1979; Combie et al., 1979; Tobin et al., 1979b; 
Kamerling et fil., 1985). When administered intramuscular or subcutaneously, the 
response peaked between 20 and 30 minutes post-injection, was erratic, and much less 
intense than after an intravenous injection (Tobin et al., 1979b). This was particularly 
interesting, for intramuscular was the method of injection reported in the racing 
industry (Tobin, 1981 ). 
Other symptoms reported to be produced upon fentanyl administration include 
tachycardia, d ecreased body temperature, and constriction of pupils (Kamerling et al., 
1985). Fentanyl has also been shown to depress equine abdominal pain syndrome 
(colic), and has clinical application to alleviate colonic spasms (Roger et al., 1985). The 
narcotic antagonist naloxone, has been shown to counteract the effects of fentanyl in 
the equine. Pretreatment with naloxone prior to fentanyl injection will completely 
block the locomotive response (Combie et al., 1981 ). 
Metabolism and elimination 
Because this research involved the administration of fentanyl to horses, the 
detection of fentanyl metabolites was equally important to detection of the parent drug. 
Even when none of the original drug was present, metabolites indicated 
administration of the parent compound. Most racing jurisdictions judge metabolite 
presence as legal evidence that the parent compound was administered. 
Because of fentanyl's high degree of lipophilicity, it requires biotransformation to 
more polar metabolites which are excreted more easily by the kidneys. The major 
metabolite discovered in the urine and plasma of the horse was N-[1-(2-phenethyl-4-
piperidinyl)] malonanilic acid, called beta-keto acid, which is formed by oxidation of 
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the propionyl side chain of the parent fentanyl molecule (Maylin, 1979; Frincke and 
Henderson, 1980; Henderson et al., 1981 ). In addition to N-[1-(2-phenethyl-4-
piperidinyl}] malonanilic acid, Maylin (1979) found approximately 10% of original 
administration excreted as despropionylfentanyl, 4-anilino-1-(2-
phenylethyl)piperidine, a metabolite formed by amide hydrolysis of the parent fentanyl 
molecule (Figure 1 ). 
It has been estimated that approximately 80-90% of the original dose is excreted in 
the equine urine as N-[1-(2-phenethyl-4-piperidinyl)] malonanilic acid within 24 hours, 
when a small dosage between 0.1 µg/kg to 0.5 µg/kg is administered. Larger doses (5.0 
µg/ kg) resulted in 50% of original dose being excreted in the urine as N-[1-(2-
phenethyl-4-piperidinyl)] malonanilic acid within 24 hours post administration 
(Maylin, 1979; Frincke and Henderson, 1980; Henderson et al., 1981). The level of 
metabolites recovered seems to be dependent on the concentration of the original 
dosage administered. 
The literature seems to indicate two major metabolic pathways within man and 
rodents for fentanyl. One pathway (Figure 2) is oxidative N-dealkyation of the parent 
molecule to norfentanyl, 4-N-(N-propionylanilino)piperidine (Van Wijngaarden and 
Soudijn, 1968; Van Rooy et al., 1981; Goromaru et al., 1982; Goromaru et al., 1984; 
Schneider and Brune, 1986). In addition to norfentanyl, other oxidative products of the 
propionyl or piperidine side chain have been identified as metaboli tes (Goromaru et 
fil., 1982; Goromaru et al., 1984). The other pathway is the same as that found in the 
equine, amide hydrolysis forming despropionylfentanyl (Maruyama and Hosoya, 1969; 
Van Rooy et al., 1981; Schneider and Brune, 1986). 
Pharma co kinetics 
The locomotor effects on the equine can be reproduced in a very short period of 
time (approximately one hour), and there is one very good reason for this 
reproducibility. The action of fentanyl within vertebrates is ended by fentanyl being 
ca rried away from the brain in the plasma. Because an intravenous injection causes a 
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Despropionylfentanyl 
Beta-keto acid 
Figure 1. Metabolic pathway of fentanyl in the equine 
Norfentanvl Despropionylfentanyl 
Figure 2. Oxidative and hydrolytic pathway of fentanyl 
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"bolus" of dose to be administered, and fentanyl is highly hydrophobic, high 
concentrations appear in tissues, organs, and the cerebrospinal fluid rather quickly, 
causing the rapid onset of action (Hess et al., 1971; Hess et al., 1972; Schleimer et al., 
1976; Ainslie et al., 1979; Hug and Murphy, 1979; Combie et al., 1979; McOain and Hug, 
1980). However, uptake rate of fentanyl by tissues and the blood brain barrier is 
regulated by the blood flow. The pharmacological action is stopped by the 
redistribution of fentanyl from the central nervous system (cerebrospinal fluid), rather 
than by metabolism (Tobin et a I., 1979b; Combie et al., 1979). Thus, the increase in 
cardiovascular and locomotor parameters occur promptly, while the respiratory and 
analgesic responses occur somewhat later and are longer in duration (Kamerling et al., 
1985). 
Although much research has been done concerning the pharmacokinetics of 
fentanyl in man, very little information is available regarding the equine. Hess et al. 
(1972), utilizing human subjects found that 10 minutes following intravenous 
injection of fentanyl, approximately 98% of the original dose had already left the blood 
stream. The organs which attain the highest concentration of fentanyl 0.5 minutes 
following intravenous administration are the lung, heart, and kidneys. Five minutes 
after administration, the areas of largest concentration are the intestinal wall, skeletal 
muscle, and liver, followed by adipose tissue which occurs at approximately 30 
minutes post administration (Hess et al., 1971 ). The concentration in gastric juice and 
stomach has also been determined, with approximately 3-4% of original dose being 
present in gastric juice, and 16% located in the stomach (Stoeckel et al., 1979). Fentanyl 
has been calculated as having a mean half-life of 20 minutes (Van Rooy et al., 1981). 
Even after 96 hours following the administration of 200 µg/ horse, urine 
concentrations in the picogram level of fentanyl equivalents could still be detected. At 
a low dose, such as 1 µg/horse, urinary concentrations of fentanyl equivalents up to 24 
hours could still be detected with assurance, further indicating fentanyl's slow 
redistribution from tissues (Tobin et al., 1986; Weckman et al., 1988). 
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Fentanyl elimination kinetics from plasma has been proposed as a three 
compartment model (Henderson et al., 1975; Schleimer et al., 1976; Michiels et al., 1977; 
Combie et al., 1979; Hug and Murphy, 1981). In the equine, the 1/2-life of the initial 
phase is approximately 3 minutes, followed by a 1/2-life of 42 minutes for the second 
phase, and a 1/2-life of 180 minutes for the final phase (Combie et al., 1981). Hug and 
Murphy (1981) hypothesize that in a three compartment model, the central 
compartment is the blood rich tissues; such as brain, kidney, heart, and lung, and the 
two peripheral compartments are muscle and adipose tissue. Initial phase may be 
reuptake of fentanyl by blood rich tissues, followed by redistribution, and the last phase 
of excretion (Lin et a I., 1981 ). 
Analysis of Fentanyl 
The analysis of biological fluids for the presence of fentanyl has been reported via a 
variety of methods ranging from the fairly basic, such as thin-layer chromatography, to 
the extremely sophisticated, such as gas chromatography I mass spectrometry. Forensic 
analyses, in general, can be catagorized as being either a screening technique or a 
confirmatory technique. Screening methods are fairly rapid, less sensitive, and contain 
a lower degree of accuracy and a corresponding higher degree of false positives. 
Confirmatory methods on the other hand are longer in duration, have a high degree of 
accuracy and sensitivity, and are less susceptible to false positive results. 
Immunoassay techniques 
lmmunochemical techniques were developed to detect specific antigens of interest 
in biological samples through the interaction with antibodies. Specifically, animals are 
challenged with a particular drug-protein complex and the antibodies produced in 
response to this immunogen are collected and purified. These antibodies are then 
used in the particular assay to test for the presence of original compound. Antibodies 
with high specificity will produce accurate and sensitive immunochemical assays. 
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When utilizing immunoassay technology as a screening procedure, several 
advantages have been noted in comparison to the classical "wet" chemistry analyses. 
Extraction of the biological sample, both urine and plasma, is usually not necessary 
when employing immunoassay, unlike the classical methods which require an acid 
hydrolysis of urine followed by liquid-liquid extraction. Plasma samples require 
extraction only. Some antibodies used for immunoassay detection can detect drug 
metabolites with similar structures to the original parent molecule. However, these 
tests do not distinguish between parent and metabolite. Several different formats of 
immunochemical detection of fentanyl and related compounds have been developed. 
Radioimmunoassay Radioirnmunoassay was developed to determine fentanyl 
equivalents in plasma and urine through the interactions with antisera . Fentanyl 
equivalents are designated as the parent fentanyl molecule and its metabolites. The 
fentanyl equivalents within the sample compete with radioactive tracers for fentanyl 
binding sites on fentanyl antibodies. The radioactive tracers can be either 1251, 3H, or 
14C. The bound and free fentanyl are separated, and the degree of radioactivity in the 
bound or unbound portion is determined using a beta scintillation counter. When 
counting the radioactivity of the unbound portion, the quantity of fentanyl equivalents 
present in the original sample would be inversely related to the amount of 
radioactivity measured. A few drawbacks to performing radioimmunoassay include 
the prospect of laboratory personnel working with radioactive material, and proper 
disposal of radiotracer materials. 
One of the earliest radioirnmunoassays for fentanyl was developed by Henderson et 
al. (1975), who obtained fentanyl antibodies by immunizing rabbits with a 
carboxyfentanyl-bovine gamma globulin conjugate, and then precipatating out the 
antibodies for use in the assay. Early antibodies developed suffered from a rather poor 
level of sensitivity (approximately 10 ng total fentanyl), and limited cross-reactivity in 
identifying fentanyl metabolites and analogs. Since that time, however, various 
investigators succeeded in improving the sensitivity and cross-reactivity of fentanyl 
radioimmunoassays through various modifications. In 1977, Michiels et al. (1977) 
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increased the sensitivity of the assay to 60 pg/ml by using 4-oxo-4{phenyl-[1-(2 
phenylethyl)-4-piperidinyl] amino) butanic acid (a fentanyl analog) conjugated to 
bovine gamma globulin as the immunogen. 
One of the commercial assays currently available for the detection of fentanyl 
equivalents is produced by Janssen Life Sciences Products (Piscataway, N . J.). The assay 
has a detection limit of 0.2 ng / ml, and limited cross-reactivity with various fentanyl 
metabolites and analogs. The conjugate used to produce the assay antibodies was not 
listed in the accompanying product information. 
In 1986, sensitivity of the fentanyl RIA was increased 100-fold down to 2 pg/ml by 
challenging with a similar immunogen to that utilized in the Janssen RIA 
(carboxyfentanyl-tyrosine methyl ester conjugate). More importantly, however, a 
radioiodinated (1251), rather than a tritium labelled (3H) analog was used in the 
competitive binding portion of the assay (Tobin et al., 1986; Woods et al., 1986; 
Weckman et al., 1988). The 125J-fentanyl antibody has acceptable crossreactivity with 
sufentanil, 3-methylfentanyl, and alpha-methylfentanyl (Tobin et al., 1986; Weckman 
et al., 1988). 
The order in which assay ingredients are added together can drastically affect the 
assay results. Schuettler and White (1984) compared results obtained when mixing 
antisera and sample followed by buffer and labelled antigen, with results when mixing 
sample and buffer followed by labelled antigen and antisera. Overestimations ranging 
from 29-76% were reporting employing the former addition sequence. The latter 
sequence allowed the labelled and unlabelled drug equal opportunity for binding sites 
on the antibody, thus producing more consistent results. Most radioimmunoassays 
recommend using this revised addition sequence. 
Enzyme-linked immunosorbent assay One of the newer immunoassay techniques 
for fentanyl detection is called enzyme-linked immunosorbent assay (ELISA). It is 
superior to RIA in terms of expense, time, simplicity, instrumentation, and it does not 
require the handling of radioactive material. The test can usually be completed in one 
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hour and the cost for reagents and ins trumentation is small compared to 
radioimmunoassay (Tobin and Blake, 1987). 
Fentanyl equivalents compete with a drug-enzyme complex for high affinity 
antibodies that are bound to a microtitre well. The microtitre well is washed, substrate 
is added, and a color change is indicative of a negative response du e to enzyme 
conversion of substrate over to colored product. No color change (known as "white-
outs") denotes a sample as possibly positive for drug of interest, due to accumulation of 
non-labelled antigen on the antibodies and enzyme unavailable for substrate 
conversion (Tobin and Blake, 1987; Weckman et al., 1988). 
The ELISA procedure is sensitive enough to detect minute quantities of fentanyl 
equivalents in plasma or urine shortly after administration . Weckman et al. (1988) 
showed that inhibition of the color change occurred at a concentration of 5.0 ng/ml. 
ELISA was shown to detect fentanyl metabolites and a fairly large number of fentanyl 
related compounds (Tobin and Blake, 1987; Weckman et al., 1988). 
Various investigators have shown that fentanyl binds with a high degree of affinity 
to plasma proteins. A lipophilic base, such as fentanyl, commonly binds to albumin 
and lipoproteins (Bickel, 1975). Only the free, unbound drug can perfuse from the 
plasma, and it could lessen the amount of parent fentanyl available in the blood 
stream to perform its locomotor effects, and the possibility of protein binding could 
lessen the amount available for metabolism and ultimate elimination from the body. 
In addition, protein binding will lessen availability of free drug for antibody 
interactions, thus increasing the possibility of false negatives. To combat this problem, 
Weckman et al. (1988) added tricarboxylic acid to denature and remove the excess 
plasma proteins, and increase the sensitivity of the assay. 
Particle concentration fluorescence immunoassay The newest addition to the 
immunoassay technology field is called particle concentration fluorescence 
immunoassay (PCFIA). Fentanyl equivalents compete with fentanyl-beta 
phycoerythrin conjugates for binding sites on fentanyl antibodies in a microtitre well. 
Following equilibration, a second antibody system is added, consisting of goat anti-
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rabbit antibody bound to latex beads. After a second incubation step, the entire sample 
is vacuum filtered through a 0.2 micron membrane present in the bottom of the 
microtitre well, resulting in a concentration of the latex beads and any fluorescent 
phycoerythrin label. Following a wash step performed under vacuum, the degree of 
fluorescence of the particles are read at a particular wavelength, and the intensity of the 
fluorescence is inversely related to the amount of free drug in the sample (McDonald 
et al., 1987). 
There is little information in the literature pertaining to fentanyl detection using 
particle concentration fluorescence immunoassay. McDonald et al. (1987) have 
estimated a threshold of sensitivity for the fentanyl PCFIA test in the order of 100 
pg / ml. In addition, excellent cross reactivity was noted with various fentanyl analogs. 
Several problems have been noted with the PCFIA assay when utilized on horse 
urines. Blank horse urines contain some degree of endogenous fluorescent materials, 
enough to cause a 15% inhibition in the binding of the fentanyl antibodies (McDonald 
et al., 1987). This could possibly lead to several false positive results. Lastly, horse 
urines contain large quantities of precipitous and mucous material, requiring removal 
by filtration through a 0.22 micron membrane filter. 
Classical chemistry methods 
Fentanyl, as previously mentioned, is metabolized completely in the equine to two 
compounds at low doses, the beta-keto acid, and despropionylfentanyl. None of the 
parent compound is present in urine. Thus, when urine is utilized as the biological 
sample for the detection of drug presence, one of the two metabolites must be used for 
confirmation of fentanyl administration. Since the beta-keto acid accounts for 
approximately 90% of the original dosage, it would seem logical that this would be the 
compound in which to target. However, the beta-keto acid metabolite is very unstable, 
especially at high temperatures, and as such is rendered useless for underivatized gas 
chromatographic injections (Gallicano and Young, 1985). The other alternative is to 
use the despropionylfentanyl metabolite for ultimate confirmation. To overcome the 
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low level of despropionylfentanyl (10%) found in the urine, a "special" acid hydrolysis 
procedure is performed in which the urine is heated under pressure in the presence of 
an acid. This hydrolyzes the beta-keto acid and forms the despropionylfentanyl 
metabolite in large enough concentration for confinnation (McDonald and Ozog, 1978). 
The acid hydrolysis procedure is not performed on plasma samples because the parent 
fentanyl molecule can be ascertained in plasma due to the small degree of metabolism 
occurring within the blood stream. 
Thin-layer chromatography Within the United States racing industry, the current 
method for initial screening of biological samples for the presence of exogenous 
constituents is liquid-liquid extraction followed by thin-layer chromatography (TLC). 
Following development of the chromatographic plate, the plate is visualized under 
short wave (254 nm) and long wave (366 nm) ultraviolet light for the presence of 
quenching and fluorescence, respectively. Lastly, the plate is subjected to a variety of 
chemical oversprays which highlight the presence of constituents within the original 
sample. 
Thin layer chromatography is used to obtain qualitative infonnation. It has been 
shown to be of poor sensitivity and is mainly used for initial forensic screening of 
biological samples. Maruyama and Hosoya (1969) report a detection limit of 2 ug for 
fentanyl by thin layer chromatography. 
Utilizing thin-layer chromatography, the Rf values of fentanyl and its metabolites 
are predictable characteristics of these compounds. The Rf value is defined as the 
distance the drug of interest migrates up the chromatographic plate relative to the 
solvent front. The Rf value will vary depending on the mobile and stationary phase 
employed. The most common TLC developing solvent employed in forensic racing 
labs for fentanyl detection is ethyl acetate/methanol/acetic acid, 8:1:1 (Maylin, 1980). 
The Rf values of standards can then be used as references to isolate and detect fentanyl 
or despropionylfentanyl on the chromatographic plate. The chemical oversprays 
commonly utilized to detect the parent fentanyl molecule or its metabolite include 
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concentrated hydrochloric acid, followed by an iodoplatinate reagent. Fentanyl and 
despropionylfentanyl react and tum blue following the iodoplatinate reagent (Maylin, 
1979). 
High-performance liquid chromatography Two high performance liquid 
chromatographic (HPLC) methods for the separation and detection of fentanyl in 
biological samples have been reported: normal phase HPLC (Frincke and Henderson, 
1980; Kumar et al., 1987), and reversed phase HPLC (Lurie et al., 1984a; Lurie et al., 
1984b). The detection method most commonly used in conjuction with HPLC is 
ultraviolet spectrophotometric detection. 
Standard fentanyl levels in the ppb range have been detected utilizing HPLC with 
the column effluent being monitored by a fixed wavelength ultraviolet detector at a 
wavelength of 195 nm (Kumar et al., 1987). In addition, Lurie et al. (1984a), have 
employed ultraviolet detection followed by absorbance ratioing of the chromatographic 
peaks to distinguish among twenty-six different fentanyl related compounds. 
Gas liquid chromatography Gas liquid chromatography can be used for drug 
confirmation by utilizing various detection methods, such as flame ionization, 
nitrogen-phosphorus thermionic detection, or mass spectrometric detection. Of the 
three, gas chromatography /mass spectrometry is the method usually required as a 
minimum for legal confirmation of drug presence in urine or plasma by most pari-
mutuel racing authorities. 
Detection and confirmation of fentanyl and its metabolites have been reported by 
gas-liquid chromatography using packed glass columns (Gillespie et al., 1981; Lin et al., 
1981; Phipps et al. , 1983a; Van Rooy et al., 1981; Kowalski et al., 1987), normal capillary 
columns (Pare et al., 1987), and fused silica megabore columns (Kowalski et al., 1987). 
Kowalski et al. (1987) report that although packed columns gave adequate selectivity 
and sensitivity to below 1 ng / ml fentanyl, the sensitivity can only be maintained for 
approximately three weeks due to column degradation. On the other hand, fused silica 
megabore columns provide adequate sensitivity for over one year. In addition, it has 
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been noted that packed columns (OV-17) occasionally "bleed", causing problems with 
the chromatographic determination of fentanyl (Van Rooy et al., 1981). 
The parent fentanyl molecule, as well as the despropionylfentanyl metabolite, can be 
detected by gas-liquid chromatography without derivatization. Several investigators, 
however, have employed derivatization to increase the sensitivity of their assay. 
Trimethylsilyl derivatives of fentanyl and its metabolites have been formed by reacting 
the sample residue with bistrimethylsilylacetamide (BSTFA) before injection into the 
gas chromatograph (Goromaru et al., 1982; Goromaru et al., 1984). Moore et al. (1986) 
were able to differentiate between fentanyl and twenty-five analogs and homologs 
upon derivatization with heptafluorobutyric anhydride in the presence of 4-
(dimethylamino) pyridine. As previously mentioned, the beta keto-acid metabolite of 
fentanyl is thermally unstable, decarboxylating at temperatures greater than 150°C. 
Gallacino and Young (1985) counteracted the thermal instability by preparing 
triflouroacetyl, trimethyl, and methyl derivatives of the compound. The 
derivatization prevented decarboxylation from occurring, resulting in useful 
chromatographic separation and detection. 
Because fentanyl contains two tertiary nitrogen atoms it is possible to use a nitrogen-
phosphorus thermionic detector for the detection of fentanyl. The nitrogen-
phosphorus thermionic detector has been shown to be approximately 10-50 times more 
sensitive to molecules containing nitrogen atoms, and is considerably more useful in 
measuring low sample concentrations than a flame-ionization d etector (Gillespie et al., 
1981). The reported detection limit of fentanyl concentration employing a nitrogen-
phosphorus detector ranged from 0.25 ng/ml (Woestenborghs et al., 1986) down to 0.02 
ng/ml (Phipps et al., 1983a), and for a flame-ionization d etector from 3.3 ng/ ml (Van 
Rooy et al., 1981) down to .5 ng/ ml (Phipps et al., 1983b). Various authors have utilized 
nitrogen-phosphorus and flame-ionization detectors in the analysis of fentanyl and its 
metabolites, employing various chromatographic parameters, columns, and obtaining 
various results (Tables 1 and 2). 
Table l. Operating conditions and detection limits of fentanyl concentrations measured by gas liquid 
chromatography using nitrogen-phosphorus or flame ionization detection. 
COLUMN CARRIER DETECTION DETECTOR 
ARTICLE SPECIFICATIONS OVEN TEMP. GAS LIMlT TYPE 
Beaumier et al., 1979 10 m x 8 mm I.D. 260oC NAa NA NPD 
Gillespie et al., 1981 2 m x 2 mm I.D. 2so0c Helium 0.1 ng/ml NPD 
van Rooy et al., 1981 1.2mx2mml.D. 2SOoC Helium 3.3 ng/ml FID 
Phipps et al., 1983a 3.05 m x 3.2 mm I. D. 290oC Helium 0.02 ng/ml NPD 
-Phipps et al., 1983b 6ft.x1/8 in. l.D. 290°c Helium 1) 0.2 ng/ml NPD -.J 
2) 0.5 ng/ml FID 
Weldon et al., 1985 2 m x 2 mm I.D. 290oC Helium 0.1 ng/ml NPD 
Woestenborghs et al., 1986 1 m x 2 mm I.D. 280oC Nitrogen 0.25 ng/ml NPD 
10 m x 0.32 m I.D. 235°C Nitrogen 0.25 ng/ml NPD 
Kowalski et al., 1987 5 m, fused silica megabore 238oC Nitrogen 0.1 ng/ml NPD 
aNA = Not available. 
Table 2. Operating conditions and detection limits of fentanyl metabolite concentrations measured by gas liquid 
chromatography using nitrogen-phosporus or flame ionization detection 
COLUMN CARRIER DETECTION DETECTOR METABOLITE(S) 
ARTICLE SPECIFICATIONS OVEN TEMP. GAS LIMIT TYPE IDENTIFIED 
Gillespie et al., 1981 2 m x 2 mm I.D. 220oC Helium subnanogram NPD 1) 4-N-anilinopiperidine 
2) Norfentanyl 
3) Despropionylfentanyl 
van Rooy et al., 1981 1.2 m x 2 mm l.D. 230oC Helium 1) .65 ng/ml FID 1) Norfentanyl 
2) 5.4 ng/ml 2) Despropionylfentanyl 
...... 
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Within most forensic racing labs, drug confirmation by gas chromatography /mass 
spectrometry is performed using positive ion collection with electron impact (El) 
ionization. Fentanyl and despropionylfentanyl fragment to form characteristic mass 
spectra, and several ions are present in both fentanyl's and despropionylfentanyl's 
mass spectra. The three major ions formed by the fragmentation of fentanyl include 
m/z 245, which results from the loss of a benzyl radical, m/z 146, which has been 
identified as a N-phenethylpiperidine cation, and m/z 189, identified as a N-
phenethylaziridium cation (Maruyama and Hosoya, 1969). The despropionylfentanyl 
compound undergoes fragmentation to three major ions as well. The m/z 280 (M+) is 
a radical cation resulting from the loss of an unpaired electron from the parent 
despropionylfentanyl compound. The other two ions are those also found in the 
fragmentation pattern of the parent fentanyl molecule, m/z 146 and m / z 189 
(Maruyama and Hosoya, 1969). 
The lowest detection limit for gas chromatography / mass spectrometry has been 
reported as 0.2 ng/ml (Lin et al., 1981). Tobin et al. (1986) indicate that endogenous 
constituents present in equine urine may correspond to approximately 10 pg/ml 
fentanyl-like material and can reach as high as 50 pg/ml, thus it is necessary to take 
into consideration the possible presence of endogenous constituents when 
confirmation of fentanyl administration is attempted via mass spectrometry. Tables 3 
and 4 list the detection limits and various other important chromatographic 
parameters employed with gas chromatography/mass spectrometry detection for 
fentanyl and its metabolites. 
Comparative studies 
Within the literature, various investigators have analyzed the detection capability 
of numerous procedures, on an individual basis, for fentanyl equivalents in biological 
samples. Two communications have compared gas liquid chromatography vs. 
radioimmunoassay. Utilizing sample spikes, Phipps et al. (1983a) chose gas liquid 
chromatography with nitrogen-phosphorus detection as the method of choice over 
Table 3. Operating conditions and detection limits of fentanyl concentrations measured by gas liquid 
chromatography using mass spectrometric detection 
ARTICLE COLUMN SPECIFICATIONS OVEN TEMP. CARRIER GAS DETECTION LIMIT 
Lin et al., 1981 0.91 m x 2 mm l.D. 235oC NAa 0.2 ng/ml 
van Rooy et al., 1981 1.2mx2mml.D. 230oC Helium NA 
Garriott et al., 1984 1.2mx2mml.D. 230-285oC Helium 0.5 ng/ml 
Goromaru et al., 1984 1 mx3mml.D. 260oC Helium NA 
Pare et al., 1987 50 m x 0.2 mm l.D. 150-2700C 200 /min Helium NA 
aNA = Not available. 
N 
0 
Table 4. Operating conditions and detection limits of fentanyl metabolite concentrations measured by gas liquid 
chromatography using mass spectrometric detection 
COLUMN CARRIER DETECTION METABOLITE(S) 
ARTICLE SPECIFICATIONS OVEN TEMP. GAS LIMIT IDENTIFIED 
Maruyama & Hosoya, 1969 NAa NA NA NA Despropionylfentany I 
Maylin, 1979 3 ft . x 2 mm l.D. 220oC NA NA Despropionylfentanyl 
Frincke & Henderson, 1980 NA NA NA NA Beta-keto Acid 
Henderson et al., 1981 NA NA NA NA Beta-keto Acid 
van Rooy et al., 1981 10 m x 0.5 mm l.D. 2100C Helium NA Despropionylfentanyl 
Norfentanyl 
Goromaru et al., 1982 1mx3 mm I.D. 130-270oC Helium NA Norfentanyl 
Goromaru et al., 1984 1mx3 mm l.D. 190oC Helium NA Norfentanyl 
aNA = Not available. 
tv -
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radioimmunoassay, citing lower expense, and a greater application and ability to 
analyze a greater variety of compounds. Woestenborgs et al. (1986), using urine 
samples from an administered animal chose radioimmunoassay as their method of 
choice. Interference from packed columns (GC/NPD) overestimated the results in 
comparison to radioimmunoassay. These two communications indicate no difference 
in the ability to detect the presence of fentanyl equivalents in biological samples, but a 
preference is indicated for the detection of fentanyl or fentanyl equivalents between the 
two assay methods. 
Few comparisons of immunoassay formats involving drugs of possible abuse have 
been reported. Hyde and Hill (1988) compared fluorescence polarization (FP), ELISA, 
and enzyme activity (EMIT) procedures for detection of opiates, barbiturates, 
amphetamines, benzodiazepines, and THC, and noted advantages and disadvantages 
of the methods. No comparison of classical to the new immunoassay methods 
including ELISA and PCFIA have been done to date. 
Summary 
Fentanyl is a very potent narcotic analgesic, used for clinical anesthesia in man. In 
the racing community, however, fentanyl is often used illicitly as a stimulant to the 
central nervous system of the equine, resulting in a significant increase in locomotor 
activity. This increase could possibly give an animal an advantage over non-drugged 
horses which it is competing against. Because of this, very sensitive and selective 
methods are necessary to ascertain the presence of fentanyl in order to control its 
criminal use in the racing industry. 
With today's current technology, many drugs including fentanyl, are at best poorly 
or not detectable in urine and blood using thin layer chromatography. The lack of 
sensitivity, compounded by the initial minute dosage, make thin layer 
chromatography an undesirable method for detection of fentanyl within the equine. 
As Tobin (1988) stated ... "while a thin layer chromatographic method for fentanyl 
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exists, this method is marginally useful, and to this author's knowledge has never 
given rise to a positive call for fentanyl." While special extraction procedures for 
fentanyl do exist, they are cumbersome and time consuming and are therefore not 
practical as a daily laboratory routine. 
Detection using immunoassay methodologies are sensitive, exhibit a great degree of 
cross-reactivity to analogs and metabolites, and are easily applied. Few studies have 
compared and elucidated the advantages and disadvantages of the classical methods 
relative to the newer immunoassay techniques. The object of this work was to 
compare characteristics of all methods for the detection of fentanyl in urine and 
plasma samples collected post the administration of the drug. 
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MATERIALS AND METHODS 
Materials 
Equine administration/collection materials and supplies 
Fentanyl citrate was obtained. from Janssen Pharmaceutica, Piscataway, NJ. Whirl-
Pak bags for initial urine collection were purchased from Fisher Scientific, Fair Lawn, 
NJ. Graduated. wide mouth specimen containers for final urine storage were obtained. 
from ABCO, Milwaukee, WI. Heparin vacutainer blood collection tubes (16 X 125 mm) 
for initial blood collection were acquired from Bectin Dickinson, Rutherford, NJ. 
Falcon® 2057 polystyrene round bottomed. tubes (17 X 100 mm) for final plasma storage 
were acquired from Bectin Dickinson, Lincoln Park, NJ. 
Solvents, chemicals and reagents 
All organic solvents used in the research were of reagent grade or better. All 
chemicals and reagents were acquired. from Fisher Scientific, Fair Lawn, NJ. including: 
acetic acid, acetone, acetonitrile, dichloromethane, ethyl acetate, concentrated 
hydrochloric acid, hexane, methanol, sodium chloride, sodium hydroxide, petroleum 
ether, isopropyl alcohol. 
Hexamethyldisilazine (HMDS) and pyridine for silanization of glassware were 
obtained. from Pierce Chemical Company, Rockford, IL., and Aldrich Chemical 
Company, Inc., Milwaukee, WI., respectively. 
All gases (nitrogen, air, helium, hydrogen, and high purity helium) for GLC and 
GC/MS were obtained from Air Products, Des Moines, IA. 
General 
Fentanyl citrate standard utilized for standard and spike preparations was obtained. 
from Janssen Pharmaceutica, Piscataway, NJ. Screw top test tubes (16 x 125 mm) with 
PTFE lined caps used in the liquid-liquid extraction s teps were purchased. from Fisher 
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Scientific, Fair Lawn, NJ. Thin layer chromatographic separations were performed 
with Merck silica gel 60 plates with F254 fluorescence indicator purchased from Cobert 
Associates, St. Louis, MO. 
Pipetrnan® precision microliter pipettes, utilized in all immunoassay procedures 
for liquid dispensation, were purchased from Rainin Instrument Company, Inc., 
Woburn, MA. A Branson 2200 Ultrasonicator, for sample sonication, was acquired 
from Branson Cleaning Equipment Co., Shelton, CT. 
Radioimmunoassay materials and supplies 
Two commercially available radioimmunoassay procedures were employed in the 
current research. Tritium labelled fentanyl RIA kits were donated by Janssen 
Pharrnaceutica, Piscataway, NJ. Iodine-125 labelled fentanyl RIA kits were donated by 
Cambridge Medical Technology Corporation, Inc., Billerica, MA. Only the reagents 
supplied by the respective kits were used in the analyses. 
Microcentrifuge tubes (1 .5 ml) employed in the RIA analyses were acquired from 
USA/Scientific Plastics, Ocala, FL. Scintiverse® BD liquid scintillation cocktail was 
purchased from Fisher Scientific, Fair Lawn, NJ. Twenty milliliter disposable 
scintillation vials were purchased from Owens-Illinois, Toledo, OH. A Packard model 
2425 Tri-Carb® liquid scintillation spectrometer system, Packard Instrument Company, 
Inc., Downers Grove, IL., was utilized in the detection of all RIA results. 
ELISA materials and supplies 
Two commercially available ELISA kits were employed in the present research. 
Two fentanyl assays were donated by the Tri-Tee Corporation, WestChester, PA. All 
other fentanyl ELISA materials were obtained from International Diagnostic Systems, 
Inc., St. Joseph, MI. Only the reagents supplied in the assay procedure were employed 
in the respective kits. Microtitre well strip holders, and a MR 600 Microplate® Reader 
for the reading of well optical density were obtained from Dynatech Laboratories, Inc., 
Chantilly, VA. 
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PCFIA materials and supplies 
The only fentanyl PCFIA kits presently available to this study were obtained from 
International Diagnostic Systems, Inc., St. Joseph, MI. The ninety-six well vacuum 
filtration plates and the Fluorescence Concentration Analyzer (FCA) for data collection, 
were acquired from Baxter-Pandex, Mundelein, IL. Spin-X® centrifuge filter units for 
urine filtration prior to PCFIA analysis, were purchased from Costar®, Cambridge, 
MA. 
High-performance liquid chromatography materials and supplies 
HPLC was performed using a Hewlett-Packard (Waldbronn, W. Germany) model 
1090 with diode array ultraviolet spectrophotometric detection. All data were stored 
and analyzed with a Hewlett-Packard series 300 chemstation data system. Samples 
were separated using a Zorbax® C-8 (4.6 mm x 25 cm) reverse phase column obtained 
from DuPont Company, Wilmington DE. Solvent A consisted of 0.1 % H3P04 (v /v), 
and 0.07% triethylamine (v/v). Solvent B consisted of 0.1% H3P04 (v/v), 0.07% 
tetraethylamine (v /v), and 80% CH3CN (v /v) . 
Gas chromatographic materials and supplies 
A Hewlett Packard model 5890 gas chromatograph equipped with a nitrogen-
phosphorus specific detector (NPD) interfaced to a computer data station was utilized 
in obtaining GC/NPD results. A Hewlett Packard model 5890 gas chromatograph 
coupled to a Hewlett Packard 5988 quadrapole mass spectrometer-data station equipped 
for electron ionization with positive ion collection was employed for mass spectral 
collection. All GC/NPD and GC/MS analysis was acquired using a DB-5 capillary 
column, 15 m X .25 mm fused silica with .25 phase loading, acquired from J & W 
Scientific, Rancho Cordova, CA. 
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Methods 
Eguine administration and sample collection 
Two mares, designated #17 and #18, each weighing approximately 750 lbs (340.2 kg), 
were administered intravenously via the left jugular, 500 µg fentanyl base (as 
Sublimaze®). Thus, the dosage each animal received was approximately 1.47 µg/ kg 
fentanyl base. Following fentanyl administration, urine and blood were collected at 
the times post administration indicated in Table 5. Urine was collected by bladder 
catheterization, and blood was collected by an intravenous catheter in the left jugular. 
At each urine collection period, all urine present in the bladder was drawn out, 
transferred to Whirl-Pak bags, and then all urines for a particular collection time were 
pooled and mixed thoroughly. The urine was dispensed evenly in graduated specimen 
Table 5. Total volume of urine and plasma collected following intravenou s 
administration of 500 µg fentanyl 
Time Post Dose Urine Plasma 
#17 #18 #17 #18 
0 Hour (Pre) 467 456 21 27 
1 Minute 22 25 
5 Minute 21 27 
10 Minute 22 27 
30 Minute 23 27 
1 Hour 233 1156 21 24 
2Hour 380 72 23 24 
4 Hour 288 625 
8 Hour 1129 983 
12 Hour 857 1083 
24 Hour 80 433 
48 Hour 697 961 
72 Hour 746 514 
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containers, capped, labelled, and stored at -20°C. At each plasma collection period, 40 
mls of blood was drawn through the catheter, placed in heparin vacutainer blood 
collection tubes, and immediately spun down at 10,000 rpm for 5 minutes. The plasma 
portion was then drawn off and all plasma for a particular collection time were pooled 
and mixed thoroughly. The plasma was then dispensed evenly in Falcon tubes, 
capped, labelled, and stored at -20°C. 
General 
Prior to use, all glassware was rinsed thoroughly with acetone to remove any 
interfering compounds. To prevent drug adsorption to glass, all conical vials utilized 
in HPLC, GLC and GC/MS analyses were initially silanized prior to use by heating at 
69°C with a 5% HMDS in pyridine solution for approximately one hour. The vials 
were then thoroughly rinsed with acetone and used in the analyses. 
RIA methods 
When performing RIA analyses, the fentanyl standard accompanying the kit was 
used for all standard preparation. The exact procedure employed for both the RIA kits 
is presented in their entirety in the Appendix. 
Although the Cambridge Medical Technology 125J fentanyl RIA kit specifies to count 
the total activity of the bound portion using a gamma counter, due to a lack of access to 
a gamma counter total radioactivity presence in the unbound portion was determined 
by a beta counter and utilized in the assessment of data. The Janssen 3H-fentanyl RIA 
kit specifies the counting of total tritium activity present in supernatant portion of 
dextran-charcoal suspension. All tritium activity was determined with a Packard 
liquid scintillation spectrometer system with a total counting time of 1 minute. 
The mean net counts for each standard and sample were expressed as a percentage of 
the mean counts of the zero standard (B0 ), with both corrected for the non-specific 
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response (NSB). The %B/B0 calculations were then utilized in all graphics and 
statistical analyses. The conversion was performed by the following equation (Eq. 1): 
standard or sample mean counts - NSB 
Eq. 1 %B/ B0 = X 100 
zero standard mean counts - NSB 
The level of radioactivity in the supernatant was inversely related to the quantity of 
fen tanyl equivalents present in the sample. 
ELISA method s 
No pretreatment after ultrasonication was necessary for plasma and urine sample 
ELISA analysis. Urine and plasma to be ana lyzed were added directly to microtitre 
wells. The complete ELISA procedures for both the Tri-Tee and the IDS fentanyl ELISA 
assays are listed in the Appendix. 
Several differences were noted between the IDS and Tri-Tee methodologies. In the 
IDS ELISA, high-affinity fentanyl antibodies are bound to the bottom of the microtitre 
wells. In the Tri-Tee ELISA, parent fentanyl molecules are bound to the bottom of the 
wells. In addition, the Tri-Tee ELISA contains a stop solution allowing for the color 
reaction to be stopped at any time following substrate addition. The IDS ELISA does 
not contain a stop solution, and relies on readings being made at consistent times post 
substrate addition for accurate and reproducible results. Following substrate addition 
optical density of the microtitre well solution was read using a MR 600 Microplate® 
Reader at wavelengths 650 nm, and 490 nm for the IDS ELISA and Tri-Tee ELISA, 
respectively. The optical d ensity of the solution was inversely related to the 
concentration of fentanyl equivalents present in the sample. 
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PCFIA methods 
No pretreatment was performed on PCFIA plasma samples, however, urine 
samples were spin filtered at 10,000 rpm for 5 minutes using Spin-X™ filtration units. 
The filtration step removed precipitate and decreased viscosity of sample. The IDS 
PCFIA procedure utilized in the research is listed in the Appendix. All reagents used 
in the PCFIA analysis were supplied by International Diagnostic Systems, Inc. All 
standards were prepared in phosphate-buffered saline (from IDS) by dilution of 
fentanyl citrate stock solution at a concentration of 1 µg/µl fentanyl base in methanol. 
After addition of all reagents in the PCFIA assay, any remaining empty wells in the 
ninety-six well assay plate were filled with distilled water. In the FCA machine, the 
entire plate was vacuum filtered at 20 mm Hg, the particles were concentrated at the 
bottom of the 0.2 micron membrane with a wash solution (from IDS), and the 
fluoresence of each well was read at an excitation/emission wavelength of 545/575 nm. 
The amount of fluorescence present was inversely related to the concentration of 
fentanyl equivalents in the sample. 
Liquid-liquid extraction (administration urines) 
For extraction of urines (both dosed and spikes) by classical liquid-liquid extraction, a 
revision of the acid hydrolysis extraction procedure described by McDonald and Ozog 
(1978) was used. Twenty-seven mls of urine for each collection time for both mare #17 
and #18 were extracted when GLC and HPLC analyses were performed. Forty-five mls 
of urine were extracted by acid hydrolysis when thin-layer chromatographic analysis 
was conducted. 
After thawing, samples were ultrasonicated for 5 minutes prior to analysis. To 
extract the fentanyl metabolites, 9 mls of urine were dispensed into each of 3 or 5 screw 
top test tubes depending on type of analysis as previously mentioned. The urines were 
acidified with concentrated HCI (saturated with NaCl) to approximately pH 2. Urines 
were extracted twice with 5 mis of dichloromethane:isopropyl alcohol (10:1). Extracts 
were combined and the dichloromethane:isopropyl alcohol phase evaporated to 
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dryness under nitrogen. To the dried residue 5 mls of 4 M HCl were added and heated 
at 15 psi (in a pressure cooker) for approximately 2 hours to allow for hydrolysis of beta-
keto acid metabolite to despropionylfentanyl (Figure 1). 
Following hydrolysis, the add solution was cooled down and washed with two 5 ml 
portions of hexane (discard organic phase). Sample was alkalinized (pH 10) with 10 M 
NaOH and extracted twice with 5 mls dichloromethane. The combined extracts were 
evaporated to dryness under nitrogen. The residue was dissolved in 2 mls of 2 M HCl 
and washed twice with 5 mls of petroluem ether. Aqueous phase was made strongly 
alkaline with 10 M NaOH and extracted three times with 4 mls petroleum ether. 
Following extraction, the petroleum ether portions were combined and evaporated 
to dryness under nitrogen. Two-hundred µls of petroleum ether were added, vortexed, 
and petroleum ether was transferred to a silanized conical vial where it was 
evaporated to dryness. Residue was dissolved in 20 µls of acetonitrile, an internal 
standard added (100 ng/ µl meperidine), then capped and vortexed for GC/NPD and 
GC/MS analysis. Four µls of the same extract were injected for GC/NPD analysis. For 
HPLC analysis, 20 µls of acetonitrile was added to residue and four µls of the final 
extract were injected through the liquid chromatograph. 
Liquid-liquid extraction (spiked urine) 
As previously mentioned, no despropionylfentanyl standard was available at a 
known concentration. Despropionylfentanyl standard was diluted with methanol 
such that 1 µI injected through the GC/ NPD produced a peak of equal height to a peak 
associated with a 1 µg injection of fentanyl standard at a concentration of 1 µg/ µl. 
Thus, the despropionylfentanyl standard was at a concentration of approximately 1 
µg/ µl fentanyl, assuming similar ionization characteristics for the two homologs. 
After thawing, 5 mls of blank urine was spiked at the following concentrations of 
despropionylfentanyl: 10 ppb, 50 ppb, 100 ppb, 250 ppb, 500 ppb, and 1 ppm. Acid 
hydrolysis of the urines was not performed as the despropionylfentanyl metabolite was 
the analyte spike, negating the usuall y necessary hydrolysis of fentanyl to 
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despropionylfentanyl (Figure 1). Extraction of the despropionylfentanyl metabolite 
spikes was performed using the same extraction procedure employed on the dosed 
urines following acid hydrolysis. 
Liguid-liguid extraction (plasmas) 
When extracting dosed plasmas for eventual analysis via gas-liquid chromatography 
and HPLC, two and four mls of plasma, respectively, at each collection time for both 
mares #17 and #18 were used. However, six mls of plasma were extracted when thin-
layer chromatographic analysis was desired. Fentanyl citrate plasma spikes were 
prepared at the following concentrations of fentanyl base in 1 ml blank plasma: 1 ppb, 
10 ppb, 25 ppb, 50 ppb, 100 ppb, 250 ppb, 500 ppb, 1 ppm, 2.5 ppm, and 5 ppm. The 1 ml 
spikes were then extracted by liquid-liquid extraction for ultimate gas-liquid 
chromatographic analysis. 
After thawing, samples were ultrasonicated for 5 minutes prior to use. Fentanyl 
extraction was carried out in 16 X 125 mm screw top test tubes. One hundred 
microliters of 4 N NaOH was added for every ml of plasma extracted. Basic plasmas 
were extracted three times with hexane, and the extracts were combined and 
evaporated to dryness under nitrogen. Two-hundred µls of hexane were added, 
vortexed, and hexane was transferred to a silanized conical vial where it was 
evaporated to dryness. Residue was dissolved in 20 µls of acetonitrile with an internal 
standard (25 ng/µl meperidine), then capped and vortexed. Four µls of the final 
solution was utilized for GC/NPD and GC/MS analyses . For HPLC analysis, 20 µls of 
acetonitrile was added to residue and four µls of the final extract were injected through 
the liquid chromatograph. 
Thin-layer chromatographic technigues 
All TLC analysis was performed on Merck silica gel 60 TLC plates, and all extracts 
were developed on the plate for a distance of 5 centimeters from the origin with ethyl 
acetate:methanol:acetic acid (8:1 :1 ). Following development, plates were visualized 
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under short wave and long wave ultraviolet light for quenching and fluorescence 
respectively. Lastly, the plates were sprayed with concentrated HCl, followed by an 
Iodoplatinate reagent (Appendix), then dipped in distilled water. Fentanyl and 
despropionylfentanyl reacted to give a dark purple band. 
High-performance liquid chromatographic techniques and conditions 
The ultraviolet range from 200-260 nm was monitored, with a linear solvent 
program over 20 minutes of 0% Bl A to 100% Bl A, then reversed back to initial 
conditions from 20-25 minutes. A solvent flow of 2 ml/ min. was used and solvents 
were degased by a steady flow of helium before each analysis. 
Gas-liquid chromatographic techniques and conditions 
J&W DB-5 fused silica columns, 15 M X .25 mm with a .25 micron loading phase 
were used for all gas-liquid chromatographic analyses (both GC/ NPD and GC/MS). All 
extracts were injected without derivatization and without thin-layer cleanup. 
Meperidine was utilized as an internal marker to allow for easier identification of 
fentanyl and despropionylfentanyl by use of relative retention times. This allowed for 
identification of peaks of interest among many peaks present in resultant 
chromatograms. Meperidine was chosen primarily due to its similar structure to 
fentanyl. 
GC/NPD analyses were performed with a Hewlett Packard 5890 GLC equipped with a 
nitrogen-phosphorus detector. The carrier gas and detector gas flows were set 
according to manufacturers specifications for maximum sensitivity. 
Conditions for GC/NPD were: 
Injector temp. 
Oven temp. (programmed) 
Detector temp. 
Bead voltage 
Carrier gas flow (helium) 
210°c 
70(hold 1 min.)-300°C; 20° / min. 
220°c 
20V 
30 ml / min. 
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Detector gas flows: 
Hydrogen 
Air 
3.5 ml/min. 
100-120 ml/min. 
Injection mode Splitless 
All GC/MS data were obtained with a Hewlett Packard 5890 GLC and a Hewlett 
Packard 5988 quadrapole MS in electron impact ionization (EI), with positive ion 
collection at 70 eV. Resolution was nominally 1 AMU with no more than 10% base 
overlap. 
Conditions for mass spectrometer GLC were: 
Injector temp. 260°C 
Oven temp. (programmed) 70(hold 1 min.)-300°C; 20° /min. 
Carrier gas Helium 
Carrier gas flow 1 ml / min. 
Injection mod e Splitless 
Conditions for mass spectrometer were: 
Electron energy 70 eV 
Source temp. 265°C 
Ionizer vacuum < 1Q-6 torr 
Dosed urines and plasmas were analyzed by GC/MS in full scan (40-550 AMU) as 
well as in single ion monitoring (SIMS) mode. Spiked urines and plasmas were 
analyzed by GC/MS using SIMS, with no full scan analyses as the most sensitive 
GC/MS technique was to be employed on the spiked samples. The ions targeted when 
employing SIMS analyses were m /e 146, m /e 189, and m/e 245 when analyzing plasma 
extracts. These three ions were used since these are the three major ions present in the 
mass spectra of fentanyl (parent). For urine extracts the ions monitored were m / e 146, 
m/e 189, and m /e 280, corresponding to the three major ions in the mass spectra of 
despropionylfentanyl. 
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RESULTS AND DISCUSSION 
Immunoassay Techniques 
Threshold values and sensitivity limits 
Diagnostic immunoasssay tests involving the use of antibodies have characteristic 
saturation points, or threshold values. The threshold value is the concentration of 
antigen at which the antibodies become completely saturated, and have no additional 
antigen binding capacity. The sensitivity limit, or lowest analyte concentration which 
the assay can positively detect, is another immunoassay characteristic. 
Resultant standard curves produced by the various immunoassays include three 
distinct regions: a region in which low sample concentrations are indistinguishable 
from a buffer blank response, a region in which the antibodies become completely 
saturated, and a region of the curve characterized as the useable portion. The useable 
portion is labelled as such because the concentration:response curve can furnish semi-
quantitative information about the concentration of the analyte of interest. 
Linear regression was performed on each region of the standard curves, producing 
three distinct lines within a standard curve for a particular assay. For this research, 
intersection of the linear regression line of the indistinguishable region with the linear 
regression line of the useable region was estimated as the sensitivity limit for the assay. 
Intersection of the linear regression line of the saturation region with the linear 
regression line of the useable region was estimated as the threshold value for the assay. 
The reproducibility of an assay is the deviation in the response of known standards on 
a daily, weekly, and monthly basis within assay lots and between assay lots. Two 
standard deviations (95% confidence level) of the percent buffer response, as indicated 
on the standard curves, were used to estimate the reproducibility of the respective 
assay on a daily / weekly basis. 
Radioimmunoassay The Cambridge Medical RIA kit uses competitive binding 
between an 1251-labelled antigen and non-labelled sample analyte for antibody sites. 
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The test was performed on two separate occasions using two individual kits, allowing 
for the construction of an overall standard curve for the assay (Figure 3). The 
sensitivity limit and threshold value of the radioimmunoassay kit was estimated as 5 
pg and 350 pg absolute fentanyl concentration, respectively (Table 6). The fairly large, 
overlapping error bars (at the 95% confidence level) indicate results from different kits 
should not be anticipated, with a high degree of confidence, to remain constant. Intra-
assay variability, however, or the variance among individual sample results on a daily 
performance was very minimal for the Cambridge Medical RIA. 
The Janssen RIA kit uses a tritium(3H)-labelled antigen in the competitive binding 
portion of the assay, and has been reported to be 100 times less sensitive than RIAs 
using an iodinated antigen (Tobin et al., 1986, Woods et al., 1986, Weckman et al., 1988). 
The Janssen assay was performed over four separate days, using a total of three separate 
assay kits. The sensitivity limit and threshold value estimated for the Janssen RIA 
were 20 pg and 5 ng absolute fentanyl concentration, respectively (Table 6) . The error 
bars (at the 95% confidence level) were the smallest for any of the irnmunochemical 
techniques analyzed, implying the assay may be performed over several occasions with 
confidence the results will remain fairly constant over that period (Figure 4). In 
addition, the intra-assay variability was very small for the Janssen RIA. 
Radioirnmunoassays using iodinated labelled antigens reportedly have increased 
sensitivity in comparison to RIAs using tritium labelled antigens (Tobin et al., 1986; 
Woods et al., 1986; Weckman et al., 1988). The Cambridge 1251 assay showed an 
increase in sensitivity on the order of 4X when compared to the Janssen 3H assay, 
although not the reported 100X. The Cambridge Medical 1251 assay had a lower 
threshold (onset to antibody saturation) in comparison to the Janssen kit, further 
illustrating the difference in antigen-antibody interaction among the RIA tests. 
Possible reasons for the differences indicated in the two tests include: antibodies 
produced in response to the irnmunogen utilized by Cambridge Medical may be more 
site-specific than the antisera utilized in the Janssen assay; iodination of the antigen for 
competitive binding may render the antigen molecule less accessible to antibody 
Figure 3. Fentanyl standard curve (buffer) from Cambridge Medical 1251-RIA performed on a total of 2 separate days 
with error bars indicating two standard deviations, n = 2 or 4 (zero corresponds to 0 pg concentration) 
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Figure 4. Fentanyl standard curve (buffer) from Janssen 3H-RIA performed on a total of 4 separate days with error bars 
indicating two standard deviations, n = 6 or 10 (zero corresponds to 0 pg concentration) 
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binding sites due to steric constrants caused by the larger iodine molecule, in tum 
allowing for more non-labelled antigen to bind to the antibody improving the overall 
sensitivity of the assay. 
ELISA The Tri-Tee ELISA assay was performed on two separate occasions using 
two different assay kits. Thirty mls of substrate buffer per o-phenylenediamine (OPD) 
tablet and 60 mls substrate buffer per OPD tablet were used in the first and second assay 
performance, respectively. Increasing the volume of substrate buffer two-fold was 
indicated in the kit instructions to increase the sensitivity of the assay two-fold as well. 
Sensitivity limit and threshold va lue estimated for the initial assay execution was 100 
pg and 750 pg total fentanyl well concentration, respectively (Table 6). A sensitivity 
limit of 20 pg total fentanyl was manifested for the second assay performance, 
revealing an increase in sensitivity with a two-fold increase in substrate buffer, as 
would be expected per the assay instructions. The intra-assay reproducibility of the Tri-
Tec ELISA was excellent, indicated by the small error bars (95% confidence level) 
within the useable portion of the standard curves (Figures 5 and 6). The point at 1000 
pg total fentanyl concentration in Figure 6, in relation to the other points in the 
useable region, contains large error bars and are noted but unexplained by the author. 
The IDS ELISA procedure was analyzed on four separate instances, using three 
different assay lots. The sensitivity limit and threshold value estimated for the IDS 
ELISA were 1.5 pg and 100 pg absolute fentanyl well concentration, respectively (Table 
6). The extremely large error bars (95% confidence level) indicate inter-assay results 
should not be anticipated to remain constant with a high degree of confidence, and the 
test should only be utilized for yes-no (positive/negative) determinations (Figure 7). 
Lack of a stop solution, for stopping substrate color reaction at a precise time post 
addition, may be a contributing factor to the large standard deviations shown. 
Substrate reacts in the well with antibody-antigen-enzyme complex until all substrate 
is converted to colored compound, unless the reaction is stopped by the addition of an 
acid solution. Thus, while reading the IDS ELISA microtitre s trips, the substrate 
Figure 5. Fentanyl standard curve (buffer) from Tri-Tee ELISA using 30 ml substrate buffer/OPD tablet with error bars 
indicating two standard deviations, n = 4 (zero corresponds to 0 pg concentration) 
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Figure 6. Fentanyl standard cu rve (buffer) from Tri-Tee ELISA using 60 ml substrate buffer/OPD tablet with error bars 
indicating two standard deviations, n = 2 (zero corresponds to 0 pg concentration) 
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Figure 7. Fentanyl standard curve (buffer) from IDS ELISA over a total of four separate days with error bars indicating 
two standard devia tions, n = 4, 6, 7, 8, 9 or 13 (zero corresponds to 0 pg concentration) 
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Table 6. Estimated detection limits and threshold values for all immunoassays 
investigated; 3H and 125RIA, Tri-Tee and IDS ELISA, and IDS PCFIA (values 
reported as absolute fentanyl concentration, with numbers in parentheses 
corresponding to concentration of buffer standard) 
Assay (mls substrate) 
125J RIA 
3HRIA 
Tri-Tee ELISA (30 mls) 
Tri-Tee ELISA (60 rnls) 
IDS ELISA 
IDS PCFIA 
Detection Limit 
5 pg (0.1 ppb) 
20 pg (0.4 ppb) 
100 pg (2 ppb) 
20 pg (0.3 ppb) 
1.5 pg (0.75 ppb) 
< 1 pg (0.05 ppb) 
Threshold Value 
350 pg (6 ppb) 
5 ng (100 ppb) 
750 pg (15 ppb) 
> 1000 pg (20 ppb) 
100 pg (5 ppb) 
80 pg (4 ppb) 
possibly was s till reacting in the wells, leading to variation in the results. Intra-assay 
variability, however, was relatively minute for the IDS ELISA. 
Due to competitive advantages (if the assay antibodies both had the same binding 
specificities) the Tri-Tee ELISA should have the greater degree of sensitivity. However, 
this was not the case when the standard curves for each assay were examined. 
Specifically, the Tri-Tee ELISA has well-bound fentanyl antigen in competition with 
sample analyte for HRP-labelled antibody binding sites. Thus, the sample analyte of 
interest and labelled antibody are mobile, and the antigen necessary for analyte 
competition is immobile. The mobile sample antigen has a greater probability of 
binding to the mobile la belled antibody than does the fixed antigen. In comparison, 
the IDS ELISA contains well-bound antibodies allowing for equal competition between 
labelled sample antigen and analyte of interest for binding sites. 
PCFIA IDS PCFIA standard curves were generated on a total of five separate 
occasions, using two different assay kits. Sensitivity limit and threshold value of the 
assay were estimated as less than 1 pg and 80 pg absolute total fentanyl well 
concentration, respectively (Table 6). The IDS PCFIA assay had the lowest sensitivity 
limit and threshold value of all the immunochemical methodologies analyzed. The 
1.5 pg absolute fentanyl corresponds to a concentration of 0.075 ng/ml which is 
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approximately 25X greater sensitivity than that reported by McDonald et al., (1987) who 
reported a sensitivity limit of 2 ng/ml for PCFIA. The error bars (95% confidence level) 
associated with the concentration:response curve reveal reproducibility is not as 
beneficial as the Janssen RIA, but superior to the IDS ELISA immunoassay (Figure 8). 
Similar to the other immunoassay methodologies, the intra-assay variation of the 
PCFIA results was exceptional, indicating results from a sample analyzed in duplicate, 
triplicate, etc, will remain fairly constant when analyzed by IDS PCFIA. 
Non-specific response 
It is imperative in any immunoassay technique to determine the non-specific 
response, that is the response of "clean" urine with the assay of interest. In an 
optimum situation, the antibodies present in the assay would register a "zero", or 
negative response with normal, non-medicated urines. However, antibodies are 
known to react to some degree with endogenous constituents present in equine urine, 
as well as plasma. This non-specific response may alter results, leading to inaccurate 
readings and possibly false positive responses. 
Radioimmunoassay Blank urine response of the 125J Cambridge Medical 
radioimmunoassay showed the assay antibodies do not react with endogenous 
constituents found in equine urine to a large degree (Figure 3). The average %B/ B0 
value manifested in the assay was approximately 101 %, with the small error bars (95% 
confidence level) indicating the assay may be performed with a high degree of 
confidence of no false positive responses. In the 3H RIA, results showed an average 
%B/ B0 response for blank urine of approximately 62.4%, extrapolating out to a 
concentration of approximately 150 pg total fentanyl well concentration (Figure 4). Of 
all the immunoassays investigated, the 3H Janssen RIA reacted to the greatest extent 
with ''blank" urines, implying individuals must be aware of the possibility of false 
positive responses due to interaction of endogenous constituents with assay antibodies. 
ELISA Both executions of the Tri-Tee ELISA indicated a "blank" response of little 
consequence to cause concern fo r false positive sample results. In the initial standard 
Figure 8. Fentanyl standard curve (buffer) from IDS PCFIA over a total of five separate days with error bars indicating 
two standard deviations, n = 4, 6, 10 or 13 (zero corresponds to 0 pg concentration) 
Q) 
en 
c 
160 
140 
120 
100 
8.. 80 
en 
CD 
a: 
.l<'. 
c 
"' ill 6 0 
ct-
40 
20 
0 
'ii % Blank Response 
0 10 JOO 
pg fen tanyl 
O Blank Urine (n = 4) 
1000 
52 
curve (30 ml/OPD) the% buffer response was approximately 108.3%, and when the 
sensitivity of the assay was increased (60 ml/OPD) the response increased as well down 
to 95.4% buffer response (Figures 5 and 6). Response from "blank" urine within the 
IDS ELISA averaged approximately 110.8% of the buffer response (Figure 7). It would 
thus seem that endogenous components do not pose a significant threat to propagate 
false positive urine responses in the IDS or Tri-Tee ELISAs, although it is still possible. 
PCFIA Endogenous compounds present in equine urine were not found to react 
with antibodies in the IDS PCFIA assay. The average% buffer response of blank urine 
was approximately 118.9% for the IDS PCFIA, and was the least reactive of all the 
immunoassays investigated with "blank" urines (Figure 8). The results infer the assay 
may be performed with a high degree of confidence no false positive sample responses 
will be propagated. 
Consequence of urine and plasma on performance (sample spikes) 
The analysis of spiked urines and plasmas to ascertain whether urine and plasma 
presence is detrimental to the assays ability to detect fentanyl and its equivalents was of 
interest in this study. The presence of urine/ plasma may consequently react with the 
antibodies in such a way as to possibly amplify or attenuate the assay response, leading 
to erroneous results. It was also of interest to determine the percent recovery of spiked 
urines and plasmas in relation to standards prepared in buffer solution. 
Cambrid~e medical RIA Analysis of spiked urines and plasmas was not performed 
on the 125J-Cambridge Medical RIA due to limited kit availability. 
Janssen RIA The percent recoveries of spiked urines for the Janssen RIA showed 
good recoveries at the lower concentrations, with the percent recovery decreasing as 
the concentration of the spike gradually increased (Table 7). Thus, at the higher 
concentrations, endogenous urine components possibly compete with the analyte for 
antibody binding sites, rendering the lower % recovery results observed. The plasma 
spikes on the other hand showed good recovery at all the concentrations analyzed, in 
contrast to the urine spikes (Table 8). 
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Tri-Tee ELISA Analysis of spiked urines and plasmas was not performed on the 
Tri-Tee ELISA due to limited kit availability. 
IDS ELISA Results from the spiked urines indicates that the IDS ELISA had 
excellent recovery of fentanyl at all concentrations employed (Table 7). The plasmas, 
however, showed excellent recovery at the very low concentrations, but at the higher 
concentrations the recovery was much less, in the range of 20-40% recovery (Table 8). 
The relatively low recoveries revealed in the plasma spikes are of interest due to the 
fact that untreated plasmas are known to decrease the efficacy of the ELISA test. Pre-
treatment of plasma with tricarboxylic acid has shown to substantially improve the 
quality of the assay (Weckman et al., 1988). Fentanyl is known to bind to a large extent 
to plasma proteins such as albumin and lipoproteins (Bickel, 1975), and the 
tricarboxylic acid hydrolyzes the fentanyl-protein bond leaving the fentanyl molecule 
available for antibody binding. It can only be assumed that upon addition to the 
"blank" plasmas, some of the fentanyl molecules bind to the plasma proteins 
rendering them invisible to the fentanyl antibodies. As no TCA pretreatment was 
performed on the plasma the overall recovery efficacy was poor, possibly leading to the 
low recovery values. 
PCFIA Similar to the results seen in the IDS ELISA assay, the IDS PCFIA showed 
good to excellent percent recovery of non-treated urines (other than Co-star filtration) 
with all concentrations having greater than 70% recovery, except for one (Table 7). It 
has been noted that blank horse urines contain endogenous materials which may 
inhibit binding capability of the antibody by as much as 15%, as well as endogenous 
quenching materials, possibly leading to the high recoveries indicated (McDonald et al. , 
1987). Also similar, and possibly due to the same cause, the plasma spikes revealed 
good recovery at low concentrations, but at the higher concentrations the ability of the 
assay to recognize the fentanyl presence decreased significantly (Table 8). The poor 
response of the spiked plasmas may be due in part to the fact that blank urines and 
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Table 7. Percent fentanyl recovery ± SEMa from spiked urines employing Janseen 
RIA, IDS ELISA, and IDS PCFIA immunochemical techniques 
Total Fentanyl 3H RIAb IDS ELJSAC IDS PCFJAd 
1 pg NDAe 110 ± 2.4 170 ± 51.9 
1.5pg NDA 237±58.9 NDA 
2pg NDA 172 ± 24.2 166 ± 24.3 
4pg NDA 149 ± 22.2 140± 7.5 
5pg 107 ± 0.2 NDA NDA 
10pg NDA 130±19.9 113 ± 28.1 
20pg NDA 101±9.2 83.3±13.1 
25pg 96.6±0.8 NDA NDA 
30pg NDA 99.0 ± 11.3 86.5 ± 5.1 
40pg NDA 69.4 ± 2.7 87.9 ±5.7 
SO pg 88.8±1.0 75.5±1.6 71.2 ± 10.6 
.1 ng 82.9±1.7 67.0±1.8 48.6±2.3 
.2ng 83.1±0.0 79.5 ± 2.3 82.7±5.8 
.4 ng 62.7±10.4 NDA NDA 
.5ng NDA 87.4±1.9 72.8±6.9 
.6ng 50.6 ±0.2 NDA NDA 
1 ng 44.7±4.7 NDA 70.2±6.9 
2ng 37.3±2.l NDA NDA 
4ng 38.2±0.2 NDA NDA 
asEM = Standard error of the mean. 
bn=2. 
Cn= 7. 
dn = 5. 
eNDA = No data available. 
plasmas contain naturally fluorescent materials, decreasing the level of fentanyl 
equivalents indicated in the sample, leading to false negative results (McDonald et al., 
1987). 
Administration urine and plasma 
The real test of an assay's usability is its capacity to detect the analyte of interest and 
its metabolites in urine or plasma from animals initially dosed with the drug. The 
longer an assay can initiate a positive response in terms of time post administration, 
the greater will be the usability and relevance to drug testing programs. 
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Table 8. Percent fentanyl recovery± SEMa from spiked plasmas employing Janseen 
RIA, IDS ELISA, and IDS PCFIA immunochemical techniques 
Total Fentanyl 3H RJAb IDS ELISAC IDS PCFIAd 
1 pg NOAe NOA 67.4±0.35 
1.Spg NOA 111±3.9 NOA 
2pg NOA 122±3.1 70.0 ± 4.1 
4pg NOA 96.8 ±3.5 70.3 ± 1.1 
5pg 124 ± 0.7 NOA NOA 
10pg NOA 81.3 ± 9.4 69.5 ±4.5 
20pg NOA 57.3±2.2 42.0± 0.67 
25pg 116 ± 0.0 NDA NOA 
30pg NOA 42.7±3.8 NOA 
40pg NDA 34.7± 2.2 36.6 ± 0.69 
SO pg 107 ± 0.7 30.7±1.5 37.3 ± 1.1 
.1 ng 112 ± 1.7 21 .7 ± 0.9 29.3 ±2.0 
.2ng 121±2.4 25.6 ± 1.8 36.8 ±2.2 
.4 ng 99.0 ±3.7 NOA NOA 
.5ng NOA 31.2 ± 2.5 33.6±2.0 
.6ng 90.5 ± 8.0 NOA NOA 
1 ng 130 ± 9.9 NOA 62.2 ± 6.0 
2ng 89.6 ±4.1 NOA NOA 
4ng 81.2 ± 4.8 NOA NOA 
asEM = Standard error of the mean. 
hn=2. 
Cn = 7. 
dn =3. 
eNDA = No data available. 
All irnmunochemical assays utilized in the current research resulted in typical 
urine and plasma profiles. The fentanyl drug and equivalents were readily detected in 
the first few collection periods post administration, with the response gradually 
returning to the pre-administration values. 
Radioimmunoassay Urine and plasma from administered horses were not 
analyzed by the Cambridge Medical 1251 RIA kit in the current research. 
The response generated by "blank" non-medicated urines complete with error bars 
denoting two standard deviations (Figures 9 and 10), shows that the Janssen 3H RIA 
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Figure 9. Urinary excretion profile produced by Janssen 3H-RIA from mare #17 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations (blank response indicated in far left) 
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Figure 10. Urinary excretion profile produced by Janssen 3H-RIA from mare #18 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations (blank response indicated in far left) 
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allowed for detection of fentanyl administration up to and including 12 hours post 
administration, at the 95% confidence level. Beyond 12 hours the error bars for both 
mares overlap with those from the "blank" urines, thus rendering the responses as 
indistinguishable from negative. The large error bars (95% confidence level) at the 1 
hour collection period in mare #17 are noted, but unexplained by the author. 
The response produced by "blank" non-medicated plasmas permitted the Janssen 
RIA kit to generate positive results up to and including 10 minutes post 
administration of fentanyl (Figures 11 and 12). The responses from the collection 
periods after 10 minutes contained over-lapping error bars at two sigma with the 
"blank" plasmas, in effect causing them to be labelled as indistinguishable from 
negative. The large error bars (95% confidence level) at the 30 minute collection time 
are noted, but unexplained by the author. 
ELISA The Tri-Tee ELISA was performed on administration samples using the 60 
mls/OPD format. The responses generated by the administered urines indicate that the 
Tri-Tee assay initiated positive results up to and including 12 hours post 
administration when compared to blank and pre-administration urines. However, 
beyond 12 hours post dose, overlapping error bars cause Mare #18 results to be 
designated as negative, similar to the Janssen 3H RIA (Figures 13 and 14). Mare #17, 
however, showed a positive response at 24 hours, with the subsequent collection 
periods responding as indistinguishable from negative. The Tri-Tee assay produced 
positive responses for plasmas at the one and five minute post dose collection periods 
for both mares #17 and #18 (Figures 15 and 16). Subsequent collection times produced 
negative values for mare #18, while mare #17 generated a positive response at 10 
minutes post dose, but beyond that overlapping error bars yielded negative results at 
the 95% confidence level. 
The urinary excretion profile produced by the IDS ELISA show positive responses 
for all hours up to and including the 24 hour collection time (Figures 17 and 18). Past 
24 hours, over-lapping error bars render the optical density values as negative to 
fentanyl presence. The responses generated by the equine plasmas show the IDS ELISA 
58 
75 
X Mare #17 (n = 3) 0 Blank Plasmas (n = 3) 
7 0 
65 ~ 60 5 5 • 
50 
0 45 co -- 40 co ~ 0 35 
30 
25 
20 
1 5 
1 0 
5 
-20 0 20 40 60 80 100 120 140 
minutes post dose 
Figure 11. Plasma profile produced by Janssen 3H-RIA from mare #17 administered 
500 µg fentanyl base with error bars indicating two standard deviations 
(blank response indicated in far left) 
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Figure 12. Plasma profile produced by Janssen 3H-RIA from mare #18 administered 
500 µg fentanyl base with error bars indicating two standard deviations 
(blank response indicated in far left) 
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Figure 13. Urinary excretion profile produced by Tri-Tee ELISA from mare #17 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations 
. 8 
<> Mare #18 (n = 2) 0 Blank Urines (n = 4) 
.7 I ~ .6 
"iii <> c: 
(IJ 
0 
. 5 
Iii 
.!:! . 4 a 
0 
. 3 
.2 0 
<> 
. 1 
- 1 0 0 1 0 20 30 40 50 60 70 8 0 
hours post dose 
Figure 14. Urinary excretion profile produced by Tri-Tee ELISA from mare #18 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations 
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Figure 15. Plasma profile produced by Tri-Tee ELISA from mare #17 administered 500 
µg fentanyl base with error bars indicating two standard deviations 
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Figure 16. Plasma profile produced by Tri-Tee ELISA from mare #18 administered 500 
µg fentanyl base with error bars indicating two standard deviations 
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Figure 17. Urinary excretion profile produced by IDS ELISA from mare #17 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations (blank response indicated in far left) 
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Figure 18. Urinary excretion profile produced by IDS ELISA from mare #18 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations (blank response indicated in far left) 
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indicating positive resu lts for all collection times for mare #17, with mare #18 showing 
positive results up to and including the 1 hour collection period (Figures 19 and 20). 
The "blank" urine response only transformed the 2 hour response of mare #18 to a 
negative, due to over-lapping error bars. It is interesting to note the IDS ELISA results 
clearly showed positive responses (at the 95% confidence level) for the farthest time 
post administration among all immunoassay methodologies utilized. 
PCFIA The administered urines produced positive responses up to and including 
the 24 hour post administration collection period (Figures 21 and 22). The responses 
for collection times beyond 24 hours contained overlapping error bars when compared 
to the pre-administration and "blank" urines. The large error bars (at the 95% 
confidence level) are noted, but unexplained by the author. No "blank" plasmas were 
analyzed by the IDS PCFIA assay, other than the plasma collected pre-drug 
administration. The dosed plasmas yielded positive responses at the one and five 
minute collection times for both mares #17 and #18 (Figures 23 and 24). Mare #17 
showed a positive response at the 10 minute period, while mare #18 produced 
negative results from 10 minutes on upward. After 10 minutes, mare #17 generated 
responses deemed as negative as well. Table 9 summarizes all the immunochemical 
techniques and their individual ability to detect fentanyl presence in equine urine and 
plasma. 
Time and ease of use 
The rapidity and ease-of-use of an assay can greatly affect its usability in forensic 
testing laboratories. Assays allowing for minimal time and personnel while at the 
same time employing relatively simple instrumentation, can be extremely 
advantageous to the racing chemist. Of all the immunoassays analyzed, the IDS PCFIA 
was the most rapid in terms of time to completion, taking approximately 30 minutes 
from start to finish of the assay. In comparison, the IDS ELISA assay and Tri-Tee ELISA 
assay on average took approximately 90 minutes and 105 minutes, respectively to 
complete. The RIA techniques took grea ter than 5 hours and 6 hours on average 
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Figure 19. Plasma profile produced by IDS ELISA from mare #17 administered 500 µg 
fentanyl base with error bars indicating two standard deviations (blank 
response indicated in far left) 
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Figure 20. Plasma profile produced by IDS ELISA from mare #18 administered 500 µg 
fentanyl base with error bars indicating two standard deviations (blank 
response indicated in far left ) 
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Figure 21. Urinary excretion profile produced by IDS PCFIA from mare #17 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations (blank response indicated in far left) 
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Figure 22. Urinary excretion profile produced by IDS PCFIA from mare #18 
administered 500 µg fentanyl base with error bars indicating two standard 
deviations (blank response indicated in far left) 
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Figure 23. Plasma profile produced by IDS PCFIA from mare #17 administered 500 µg 
fentanyl base with error bars indicating two standard deviations, n = 3 
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Figure 24. Plasma profile produced by IDS PCFIA from mare #18 administered 500 µg 
fentanyl base with error bars indicating two standard d eviations, n = 3 
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respectively, for the 1251-RIA and 3H-RIA to generate results using liquid scintillation 
counting. Table 9 lists the respective assays and their average time to completion in 
the current research. The time necessary to complete an assay will vary according to 
the number of samples tested, and can be facilitated much more rapidly through the 
use of repeater pipettes for rapid reagent addition. 
All the immunoassays were fairly easy to perform as they all were of a "recipe" 
format. The RlAs were the most difficult and cumbersome of the immunochemical 
assays to perform due to the fact that handling of radioisotopes was necessary for assay 
execution, requiring precautions to be employed because of the radioactive presence. 
Also, when comparing the RIAs individually, the Cambridge Medical assay was easier 
to perform than the Janssen assay as the directions included in the kit were much 
clearer, the reagents were easier to prepare, and was overall less time consuming. Due 
to a lack of radioactivity in the ELISA and PCFIA kits, these assays were able to be 
performed rapidly, with little difficulty in terms of assay execution. 
In terms of instrumentation, the RlAs necessitated the use of a liquid scintillation 
counter, and although not difficult to operate it, does require some experience to 
generate accurate and reproducible results. An advantageous feature of ELISA 
methods is the ability to interpret results strictly "by eye", without the need of a reader 
Table 9. Latest collection times post administration of fentanyl (500 µg) generating 
positive responses (2 S.D.) for both urine and plasma from mares #17 and #1 8, 
and total time to completion of the assay procedure for all immunochemical 
techniques analyzed 
Assay Urine Plasma Time to Completion 
125J-RIA ND A a NOA > 5 Hours 
3H-RIA 12 Hour 10 Minute > 6 Hours 
Tri-Tee ELISA 12 Hour 5 Minute 1 Hour; 45 Minutes 
IDS ELISA 24 Hour 1 Hour 1 Hour; 30 Minutes 
IDS PCFIA 24 Hour 5 Minute 30 Minutes 
aNDA =No data available. 
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to generate results. In this manner the slightest color indication in the well would 
constitute a negative response, with clear wells (white-outs) denoting possible positive 
responses. Although a reader is not necessary to perform the assay, it is highly 
recommended as unknown samples producing a slight color reaction would be 
interpreted as negative without a reader, but probably deemed suspicious when a 
reader is utilized. This type of instrument is easy to operate and can be programmed so 
that results can be automatically generated. The PCFIA utilizes an FCA machine, and 
although not extremely difficult to operate, does require some practice to become 
familiar with the various parameters available. This instrument is also programmed 
to automatically generate reports. 
Classical Techniques 
Within the forensic drug testing community, the accepted method of screening 
urine and plasma samples for illicit compounds is by thin-layer chromatographic 
separation, followed by visualization with various chemical oversprays. It has long 
been known that thin-layer chromatography (TLC), although the accepted method, is a 
limited methodology with unsatisfactory detection limits for a wide variety of 
compounds of interest to the racing chemist. High performance liquid 
chromatography (HPLC) with ultraviolet spectrophotometric detection, although 
superior to TLC techniques in the ability to ascertain drug presence, is generally 
utilized as a screening technique rather than a confirming one. Gas chromatography 
with nitrogen-phosphorus thermionic or flame ionization detection are used as 
screening techniques, and occasionally in a confirmatory capacity. Gas 
chromatography /mass spectrometry methods, however, are designated and utilized 
specifically as confirmatory analyses when samples have been deemed suspicious by 
screening procedures. 
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Limit of detection 
By comparing the detection limits of the various methods, some generalities can be 
made regarding the usability of the respective chromatographic techniques. A 
despropionylfentanyl standard at a known concentration was unavailable for the 
determination of a detection limit by any of the chromatographic systems. 
TLC For all thin-layer work, the TLC plates were developed for a distance of five 
centimeters with a solvent consisting of ethyl acetate:methanol:acetic add (8:1 :1 ). 
Following development the plates were sprayed with a chemical overspray sequence of 
concentrated HCl-iodoplatenate-water, and the spots of interest were then visible on 
the plate. Following plating and development of fentanyl and despropionylfentanyl 
standards on the TLC plate, quenching was observed under SWUV for the 
despropionylfentanyl compound, while the parent molecule indicated neither 
quenching nor fluorescence following UV visualization. The Rf values for fentanyl 
and despropionylfentanyl were 0.30 and 0.54 , respectively. 
Concentrations of 20, 15, 10, 5, 2, 1, 0.75, 0.5, 0.25, and 0.1 µg fentanyl present on the 
TLC plate were developed, visualized under UV light, and then sprayed with the 
aforementioned spray sequence. All concentrations higher than, and including 1 µg, 
were plainly visible to the naked eye at the Rf value of interest. Below 0.75 µg fentanyl 
the ability to visualize the spot of interest with the naked eye was greatly impaired and 
extremely difficult. When taken into context that an actual TLC plate would contain a 
large number of samples, each with endogenous constituents becoming visible 
following spraying, the detection limit of fentanyl would have to be classified as 
approximately 1 µg on the TLC plate. This is consistent with the resu lts of Maruyama 
and Hosoya (1969) who reported a detection limit of 2 µg for fentanyl by TLC. 
HPLC The results seem to indicate the limit of detection for fentanyl by HPLC 
with ultraviolet spectrophotometric detection and the parameters listed in the 
Materials and Methods is equal to approximately 0.5 µg on column. Figure 25 shows a 
fentanyl standard curve by HPLC in terms of total quantity of fentanyl on column. 
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GC/NPD Gas chromatography with nitrogen-phosphorus thermionic detection 
had a detection limit for fentanyl equal to approximately 2.0 ng on column. However, 
the sensitivity may decrease when actual samples are injected, due to the possibility of 
endogenous interferences at the retention time of fentanyl in the chromatogram. 
Figure 26 shows a fentanyl standard curve by GC/NPD. 
GC/MS Gas chromatography/ mass spectrometry detection in full SCAN and 
SIMS mode had detection limits for fentanyl equal to approximately 10 ng and 2 ng on 
column, respectively. Figures 27 and 28 show fentanyl standard curves by GC/ MS in 
full SCAN and SIMS mode, respectively. 
Sample spikes 
Extraction of despropionylfentanyl urine spikes and fentanyl plasma spikes was 
performed to determine if the extraction techniques employed were removing enough 
of the analyte of interest for adequate chromatographic analysis. 
TLC No thin-layer analysis of urine or plasma spikes was p erformed in the 
current research. 
HPLC No high-performance liquid chromatographic analysis of urine or plasma 
spikes was performed in the current research. 
GC/ NPD Five mls of blank equine urine was spiked with despropionylfentanyl 
and then extracted by the acid hydrolysis procedure indicated in the Materials and 
Methods without the hydrolysis step being performed under acidic conditions in the 
pressure cooker. Urines were spiked at the following concentrations: 10, 50, 100, 250, 
500, and 1000 ppb despropionylfentanyl. Table 10 shows the percent recovery of the 
despropionylfentanyl spikes by GC/ NPD. The results indicate that at all concentrations 
listed, recovery of despropionylfentanyl approached or exceeded 100% indicating 
adequate recovery of despropionylfentanyl from the equine urine. 
One ml of blank equine plasma was spiked with fentanyl at 10, 50, 100, 250, 500, and 
1000 ppb and then extracted by the base extraction procedure indicated in the Mater ials 
and Methods. Table 11 shows the percent recovery of the fentanyl plasma spikes by 
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Figure 25. Fentanyl standard curve by high-performance liquid chromatography with 
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Figure 26. Fentanyl standard curve by gas chromatography using nitrogen-phosphorus 
thermionic detection, n = 1 
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Figure 27. Fentanyl standard curve by gas chromatography with mass spectrometric 
detection in full scan mode, n = 1 
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Figure 28. Fentanyl standard curve by gas chromatography with mass spectrometric 
detection in SIMS mode, n = 1 
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Table 10. Percent recovery of despropionylfentanyl urine spikes by GC/NPD (n = 1) 
101212b 501212b o.11212m 0.251212m o.51212m 1 1212m 
Spikea 20 28.1 53.7 164.6 414.7 550.7 
Standardb 3.5 16.7 137.9 167.9 440.9 552.6 
% Recovery 56.9 168.3 256.7 98.0 94.1 99.7 
aSample spike (area X 100). 
bstandard (area X 100). 
Table 11. Percent recovery of fentanyl plasma spikes by GC/NPD (n = 1) 
101212b 501212b 0.1 1212m 0.251212m 0.51212m 1 1212m 
Spikea 13.3 65.5 78.9 234.8 330.4 977.7 
Standardb 15.5 72.8 93.4 205.1 390.2 989.7 
% Recovery 85.6 90.0 84.5 114.5 84.7 98.8 
asample spike (area x 100). 
bstandard (area X 100). 
GC/NPD following base extraction. The results indicate that at all concentrations 
listed, recovery of fentanyl approached or exceeded 100%, indicating adequate recovery 
of the parent fentanyl molecule from plasma using base extraction techniques. 
GC/MS Within the forensic racing community, gas chromatography followed by 
mass spectrometric detection is the current accepted method of choice for legal 
identification and confirmation of drug presence within a particular sample of interest. 
For despropionylfentanyl urine spikes and fentanyl plasma spikes, abundance of ion 
m/e 146 was used to determine percent recovery by GC/MS in single ion monitoring 
mode (SIMS). Tables 12 and 13 indicate the percent recovery of the 
despropionylfentanyl urine and fentanyl plasma spikes by GC/MS in single ion 
monitoring mode following acid hydrolysis and base extraction, respectively. The 
results indicate that at all concentrations listed, recovery of fentanyl approached or 
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Table 12. Percent recovery of despropionylfentanyl urine spikes by GC/MS (n = 1) 
101212b 501212b 0.1 1212m 0.251212m 
Spikea 71.4 586.9 2899.0 28421 
Standardb 78.6 567.4 1309.2 2560.5 
% Recovery 90.8 103.5 221 .4 111 .0 
aion abundance (m/e 146) X 1000 of sample spike. 
bJon abundance (m/e 146) X 1000 of standard. 
0.5 1212m 
5811 .7 
5298.7 
109.7 
Table 13. Percent recovery of fentanyl plasma spikes by GC/MS (n = 1) 
101mb 501212b 0.1 1212m 0.25i;mm 
Spikea 19.5 141.6 227.0 532.4 
Standardb 16.0 153.8 170.2 582.8 
% Recovery 121.9 92.0 133.4 91.3 
aion abundance (m/e 146) X 1000 of sample spike. 
bJon abundance (m/ e 146) X 1000 of standard. 
0.51212m 
1164.9 
1312.3 
88.8 
1 1212m 
7237.6 
6852.6 
105.6 
1 1212m 
2324.6 
2377.8 
97.8 
exceeded 100%, indicating good recovery of despropionylfentanyl and parent fentanyl 
molecule from urine and plasma by the extraction techniques utilized, coinciding with 
the GC/NPD results. 
Administration urines 
Thin-layer chromatog-ra12hy Analysis of administration urines from both mares 
#17 and #18, 45 mls of urine were acid hydrolyzed according to the revision of the 
McDonald and Ozog (1978) procedure previously described. The results indicate that at 
the administered dose (1.47 µg/kg), presence of the beta-keto acid hydrolysis product, 
despropionylfentanyl, can be detected according to the currently accepted thin-layer 
parameters up to approximately 8 hours post administration when 45 mls of urine are 
used in the analysis. From 1 hour to 8 hours post dose, visualization to the naked eye 
of original fentanyl administration (due to despropionylfentanyl presence) was 
possible in both animals. After 8 hours post dose, neither the presence of 
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despropionylfentanyl or parent fentanyl was indicated on the plate following TLC 
analysis (Pictures 1 and 2). 
It must be kept in mind that the add hydrolysis procedure and iodoplatenate spray 
sequence are unique techniques, designed specifically for the ascertation of fentanyl 
and fentanyl-like compounds in urine or plasma. Thus, these techniques are usually 
not part of the daily practices of forensic racing laboratories, and are only performed 
when samples enter the lab labelled as needing special attention for fentanyl-like 
compounds. 
HPLC High performance liquid chromatographic analysis of the administration 
urines and plasmas was performed assuming no prior knowledge of previous fentanyl 
administration. Within the Racing Chemistry Laboratory at Iowa State University, all 
unknown samples requiring HPLC-UV diode array analysis are analyzed by 
monitoring the ultraviolet range of 200-260 nm, as most compounds will absorb 
ultra vio let light within that 60 nm range. Utilizing the procedure indicated in the 
Materials and Methods, the presence of despropionylfentanyl following hydrolysis of 
twenty-seven mls post administration urines (#17 and #18) was not indicated in any of 
the hours post dose. Thus, HPLC with ultraviolet spectrophotometric detection was 
not sufficiently sensitive to detect fentanyl administration (by despropionylfentanyl 
presence) when 500 µg fentanyl was the original administration dosage. 
GC/NPD Acid hyd rolysis of twenty-seven mls of urine was performed three times 
and the results were averaged for each hour post dose. When analyzing the total area 
under the despropionylfentanyl peak in the chromatogram following acid hydrolysis, 
mares #17 and #18 both seem to reach maximum excretion of fentanyl metabolites in 
the urine at 2 hours post administration (Figures 29 and 30). An extremely important 
fac tor as to whether fentanyl equivalents will be detected in urine would be the acid 
hydrolysis step, and complete hydrolysis of the beta-keto add metabolite over to 
despropionylfentanyl at the appropriate psi is essential for the detection of fentanyl 
administration in urine. The farthest time post administration in which 
despropionylfentanyl was detected by GC/ NPD was 24 hours post administration in 
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Spray sequence= concentrated HCl: iodoplatenate reagent: H20 
Picture 1. Thin-layer chroma to graphic results from mare #17 following acid 
hydrolysis of forty-five mis urine 
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Spray sequence= concentrated HCl: iodoplatenate reagent: H20 
Picture 2. Thin-layer chromatographic results from mare #18 following acid 
hydrolysis of forty-five mls urine 
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Figure 29. Urinary excretion profile of mare #17 by GC/NPD following acid hydrolysis, 
n=3 
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Figure 30. Urinary excretion profile of mare #18 by GC/NPD following acid hydrolysis, 
n=3 
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both mares #17 and #18 (Table 14). Results from pre-administration urines indicate 
endogenous constituents elute from the column at approximately the same time as 
despropionylfentanyl and must be taken into account when analyzing GC/NPD 
chromatograms. 
GC/MS When analyzing the total abundance of ions m/e 146, m/e 189, and m/e 
280 in full SCAN and SIMS mode, mares #17 and #18 both reach maximum excretion 
of fentanyl metabolites in the urine at 2 hours post administration which is consistent 
with the GC/NPD results (Figures 31 through 34). Using full SCAN analysis, the 
farthest time post administration in which despropionylfentanyl was detectable by the 
presence of all three major ions (m/ e 146, m / e 189, and m / e 280) was 12 hours post 
dose in both mares #17 and #18 (Table 15). However, using SIMS analysis, the farthest 
time post administration was increased to 24 hours in which the presence of the three 
major ions of despropionylfentanyl were present in the urine of both mares #17 and 
#18 (Table 16). 
It must be kept in mind, however, that initial mass spectral analysis of suspicious 
samples is routinely performed in full SCAN mode. The SCAN run allows for all ions 
within the sample to be detected, and then when an exogenous drug is thought to be 
present SIMS analysis can be performed by selectively looking at specific ions within 
the chromatogram. For samples to be run initially in SIMS mode, an indication of 
drug presence must be known prior to analysis in order to select the ions of interest for 
mass spectral detection. 
Administration plasmas 
TLC For thin-layer analysis of the administration plasmas, 6 mls of plasma were 
extracted according to the base hydrolysis procedure previously described. As pictures 3 
and 4 indicate, at the dose administered, no parent fentanyl was observed in the 
plasma at any of the collection times post dose following spraying. Two factors may 
have contributed to the results obtained: a) fentanyl is a very hydrophobic compound, 
and b) the initial d ose (1 .47 µg / kg) was small in rela tion to concentra tions known to 
Table 14. Average peak area (despropionylfentanyl) of urine from mares #17 and #18 by GCINPD 
following acid hydrolysis (n = 3) 
Mare #17 
0 Hr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72Hr 
Peak Areaa 2.8 799.8 1290.2 478.0 83.6 26.7 9.8b NOAC NDA 
% RSo<l 86.8 25.1 29.7 41 .6 53.9 45.7 1.4 NIAe NIA 
Mare #18 
0 Hr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72 Hr 
Peak Area NDA 338.9 1048.8 481.1 203.9 125.2 19.4 NDA NOA 
% RSD NIA 90.3 104.l 115.4 118.7 106.2 70.6 NIA NIA 
areak area X 100. 
bn =2. 
CNo detectable amount. 
<lRela tive standard deviation as % of the mean. 
eNot available. 
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Figure 31 . Mare #17 urinary excretion profiles following administration of 500 µg 
fentanyl i.v. by GC/MS in full SCAN mode, n = 3 
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Figure 32. Mare #18 urinary excretion profiles following administration of 500 µg 
fentanyl i.v. by GC/ MS in full SCAN mode, n = 3 
Table 15. Average ion abundance (despropionylfentanyl) of urine from mares #17 and #18 by 
GCIMS in full SCAN mode following acid hydrolysis (n = 3) 
Mare #17 
mLe 146 
OHr 1 Hr 2 Hr 4Hr 8 Hr 12 Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance'! ND Ab 613.4 718.9 330.9 155.3 22.0 NOA NOA NOA 
% RSOC NI Ad 73.2 23.3 58.6 81.9 100.4 NIA NIA NIA 
mLe 189 
0 Hr 1 Hr 2Hr 4Hr 8 Hr 12 Hr 24Hr 48 Hr 72Hr 
Ion Abundance NOA 458.2 538.7 252.6 133.6 16.0 NOA NOA NOA 
% RSO NIA 12.0 28.1 56.S 82.2 106.9 NIA NIA NIA 
mLe 280 
OHr 1 Hr 2Hr 4Hr 8 Hr 12 Hr 24 Hr 48Hr 72Hr 
Ion Abundance NDA 34.4 44.5 19.1 10.7 1.7 NOA NOA NOA 
% RSO NIA 15.7 30.8 64.9 94.4 173.1 NIA NIA NIA 
Mare #18 
mLe 146 
0 Hr 1 Hr 2Hr 4Hr 8Hr 12 Hr 24 Hr 48 Hr 72Hr 
Ion Abundance NDA 76.3 845.2e 210.8 76.7 55.6 4.7 NOA NOA 
% RSO NIA 73.8 111.3 91.S 96.1 77.8 86.8 NIA NIA 
mLe 189 
0 Hr 1 Hr 2 Hr 4 Hr 8Hr 12Hr 24 Hr 48Hr 72Hr 
Ion Abundance NOA 65.4 570.5e 179.6 62.9 45.5 4.1 NOA NDA 
% RSO NIA 69.9 109.1 100.8 97.2 78.9 87.2 NIA NIA 
mLe 280 
0 Hr 1 Hr 2 Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72Hr 
Ion Abundance NOA 5.6 28.7e 16.7 4.9 4.8 NOA NDA NDA 
% RSO NIA 81.9 97.0 116.5 136.0 74.9 NIA NIA NIA 
aJon abundance X 100. 00 
hNo detectable amount. 
N 
CRelative standard deviation as % of the mean. 
dNot available. 
en= 2. 
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Figure 33. Mare #17 urinary excretion profiles following administration of 500 µg 
fentanyl i.v. by GC/MS in SIMS mode, n = 3 
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Figure 34. Mare #18 urinary excretion profiles following administration of 500 µg 
fentanyl i.v. by GC/MS in SIMS mode, n = 3 
Table 16. Average ion abundance (despropionylfentanyl) of urine from mares #17 and #18 by 
GC/MS in single ion monitoring mode fo llowing acid hydrolysis (n = 3) 
Mare #17 
mLe 146 
OHr 1 Hr 2Hr 4 Hr 8 Hr 12 Hr 24 Hr 48 Hr 72Hr 
Ion Abundance'l ND Ab 1339.8 1571 .6 809.5 354.3 67.4 23.oc 2.2 2.0 
% RSDd N/Ae 31.9 19.4 68.6 82.1 82.7 NIA 65.4 95.1 
mLe 189 
OHr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72Hr 
Ion Abundance NDA 924.6 998.0 654.6 247.0 46.5 13.7e 1.6 1.2 
% RSD NIA 31.6 14.1 79.3 81.3 85.9 NIA 63.1 60.3 
mLe 280 
OHr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance NDA 80.6 82.9 64.4 22.0 3.7 NDAe 0.13 0.07 
% RSD NIA 41.9 25.4 87.4 83.3 90.9 NIA 172.5 172.0 
Mare #18 
m Le 146 
0 Hr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance NDA 275.4 567.~ 473.5 161 .0 156.4 15.6 1.2 0.6 
% RSD NIA 80.3 NIA 36.8 73.6 83.4 106.1 48.2 111.3 
mLe 189 
OHr 1 Hr 2Hr 4 Hr 8 Hr 12 Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance NOA 194.7 344_4e 337.3 122.4 112.8 11 .9 1.0 02 
% RSO NIA 83.2 NIA 32.2 78.2 82.6 103.8 47.8 173.3 
mLe280 
OHr 1 Hr 2Hr 4 Hr 8Hr 12 Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance NOA 12.8 18.4e 20.5 8.6 6.6 0.7 NO A NOA 
% RSD NIA 105.9 NIA 53.7 104.2 75.8 79.6 NIA NIA 
aron abundance x 1000. 00 
Vt 
hNo detectable amount. 
Cn = 1. 
dRelative standard deviation as % of the mean. 
eNot available. 
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Spray sequence = concentrated HCl: iodoplatenate reagent: H20 
Picture 3. Thin-layer chroma tographic results from mare #17 fo llowing base extraction 
of six mis plasma 
Table 16. Average ion abund ance (despropionylfentanyl) of urine from mares #17 and #18 by 
GCIMS in single ion monitoring mode following acid hydrolysis (n = 3) 
Mare #17 
mLe 146 
OHr 1 Hr 2Hr 4 Hr 8 Hr 12 Hr 24 Hr 48 Hr 72Hr 
Ion Abundance" NO Ab 1339.8 1571 .6 809.5 354.3 67.4 23.oc 2.2 2.0 
% RSod NIAe 31.9 19.4 68.6 82.1 82.7 NIA 65.4 95.1 
mLe 189 
OHr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72Hr 
Ion Abundance NDA 924.6 998.0 654.6 247.0 46.5 13.7e 1.6 1.2 
% RSO NIA 31 .6 14.1 79.3 81 .3 85.9 NIA 63.1 60.3 
mLe 280 
0 Hr 1 Hr 2 Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance NOA 80.6 82.9 64.4 22.0 3.7 NOAC 0.13 0.07 
% RSO NIA 41.9 25.4 87.4 83.3 90.9 NIA 172.5 172.0 
Mare #18 
mLe 146 
0 Hr 1 Hr 2Hr 4 Hr 8 Hr 12Hr 24 Hr 48 Hr 72 Hr 
Ion Abundance NOA 275.4 567.9C 473.5 161 .0 156.4 15.6 1.2 0.6 
% RSO NIA 80.3 NIA 36.8 73.6 83.4 106.1 48.2 111.3 
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cause rapid and reliable pharmacological responses in the equine (Tobin et al., 1979b; 
Combie et al., 1979). Thus, the rather small quantity of fentanyl could have been 
absorbed into the tissues at such a rapid rate that after several minutes the quantity 
available in the blood stream was too minute for TLC analysis. 
HPLC Presence of fentanyl following extraction of six mls post administration 
plasmas (#17 and #18) was not indicated in any of the collections post administration. 
Thus, HPLC with ultraviolet spectrophotometric detection at 200-260 nm was not 
sufficiently sensitive enough to detect fentanyl administration in plasma when 500 µg 
fentanyl was the original administration dosage. 
GC/NPD Base extraction of two mls of plasma was performed three times and the 
results were averaged for each hour post dose. When analyzing the total area under 
the fentanyl peak in the chromatogram following injection, mares #17 and #18 both 
reach maximum fentanyl levels in the blood stream at 1 minute post administration 
(Figures 35 and 36). The presence of despropionylfentanyl was indicated in both mares 
up to and including 10 minutes post administration. Peak area decreased to near 
background values at 30 minutes post administration and remained at background in 
the subsequent collections. In addition, the GC/NPD results indicate the presence of 
endogenous constituents which elute at approximately the same retention time as 
fentanyl (Table 17). 
GC/MS In agreement with the GC/NPD results, abundance of ions m/e 146, m/e 
189, and m/e 245 in full SCAN and SIMS mode show mares #17 and #18 reach 
maximum plasma fentanyl concentration at 1 minute post administration (Figures 37 
through 40). Using full SCAN analysis, the farthest time post administration in which 
fentanyl was detectable by the presence of all three major ions (m/ e 146, m / e 189, and 
m / e 245) was 5 minutes post dose for both mares #17 and #18 (Table 18). Using SIMS 
analysis, the farthest time post administration was increased to 10 minutes for mare 
#17 and 30 minutes for mare #18 by the presence of all three major ions of fentanyl. 
(Table 19). 
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Figure 35. Plasma profile of mare #17 by GC/ NPD following base extraction, n = 3 
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Figure 36. Plasma profil e of mare #18 by GC/NPD fo llowing base extraction, n = 3 
Table 17. Average peak area (fentanyl) of plasma from mares #17 and #1 8 by GC/NPD following 
base extraction (n = 3) 
Mare #17 
0 Hr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Peak Areaa 5.5 62.0 14.7 9.0 5.5 6.7 5.4 
%RSDb 49.5 16.0 14.3 61.1 20.0 71 .6 40.7 
Mare #18 
OHr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Peak Area 2.8 44.5 9.5 7.8 4.1 5.3 8.7 
%RSD 103.6 34.8 43.2 39.7 107.3 35.8 94.3 
areak area X 100. 
bRelative standard deviation as % of the mean. 
\0 
0 
9 1 
O m/e 146 O m/e 189 /Ji. m/e 245 
3 
2.5 
0 
0 2 
1.5 
.5 
- . 5 ~--...--~~--~~~~--~-----...----~...----......--.-~-r-~~--..---. 
- 1 0 0 1 0 20 30 40 50 60 70 
minutes post dose 
Figure 37. Mare #17 plasma profiles following administration of 500 µg fen tanyl i.v. by 
GC/ MS in full SCAN mode, n = 3 
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Figure 38. Mare #1 8 plasma profiles following administration of 500 µg fentanyl i.v . by 
GC/ MS in full SCAN mode, n = 3 
Table 18. Average ion abundance (fentanyl) of plasma from mares #17 and #18 by GCIMS in full 
SCAN mode following base extraction (n = 3) 
Mare #17 
mLe 146 
0 Hr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundancea ND Ab 23 0.6 NOA NOA NOA NOA 
% RSOC NI Ad 14.6 93.3 NIA NIA NIA NIA 
mLe 189 
OHr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NDA 1.6 0.42 NOA NOA NOA NOA 
% RSO NIA 9.9 85.7 NIA NIA NIA NIA 
mLe 245 
OHr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NOA 28 0.64 NOA NOA NOA NOA 
% RSO NIA 22.9 92.7 NIA NIA NIA NIA 
Mare #1 8 
mLe 146 
OHr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NDA 28.1 3.6 27 NOA NOA NOA 
% RSO NIA 54.6 173.0 170.7 NIA NIA NIA 
mLe 189 
0 Hr 1 Min SMin 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NDA 16.5 3.0 NOA NOA NOA NOA 
% RSO NIA 44.8 173.2 NIA NIA NIA NIA 
mLe 245 
0 Hr 1 Min 5 Min 10 Min 30Min 1 Hr 2Hr 
Ion Abundance NDA 42.7 7.7 8.0 NOA NOA NOA 
% RSO NIA 78.7 102.6 44.3 NIA NIA NIA 
a1on abundance X 100. \0 
bNo detectable amount. 
w 
CRelative standard deviation as % of the mean. 
dNot available. 
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Figure 39. Mare #17 plasma profiles following administration of 500 µg fentanyl i.v. by 
GC/ MS in SIMS mode, n = 3 
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Figure 40. Mare #18 plasma profiles following administra tion of 500 µg fentanyl i.v . by 
GC/MS in SIMS mode, n = 3 
Table 19. Average ion abundance (fentanyl) of plasma from mares #17 and #18 by GCIMS in 
single ion monitoring mode following base extraction (n = 3) 
Mare #17 
mLe 146 
0 Hr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundancea NO Ab 60.3 11 .6 5.0 2.4 NOA NOA 
% RSOC NI Ad 49.6 52.6 114.0 87.5 NIA NIA 
mLe 189 
0 Hr 1 Min 5Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NOA 31.4 5.1 20 NOA NDA NDA 
% RSO NIA 49.4 41.2 175.0 NIA NIA NIA 
mLe 245 
0 Hr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NOA 108.1 19.2 8.2 4.1 NDA NOA 
% RSO NIA 53.9 56.8 101 .2 51.2 NI A NIA 
Mare #18 
mLe 146 
0 Hr 1 Min 5Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NOA 618.4 86.6 80.0 19.1 7.0 NOA 
% RSO NIA 81.6 101.0 96.4 173.8 171.4 NIA 
mLe 189 
OHr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NOA 326.5 46.5 30.2 9.1 NOA NDA 
% RSD NIA 83.2 114.8 90.4 173.6 NIA NIA 
mLe 245 
OHr 1 Min 5 Min 10 Min 30 Min 1 Hr 2 Hr 
Ion Abundance NDA 509.5 64.4 49.9 13.9 8.1 NOA 
% RSD NIA 77.8 108.4 92.8 173.4 174.1 NIA 
a1on abundance X 100. 
bNo detectable amount. \0 
CRelative standard deviation as % of the mean. 
0\ 
dNot available. 
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Table 16. Fentanyl detection limits and latest collection times post dose indicating 
original fentanyl administration (500 µg) in both urine and plasma from 
mares #17 and #18 by classical detection techniques 
Urine (mis) 
Technique #17 #18 
TLC 8 Hr (45) 8 Hr (45) 
HPLC (UV) NDA (27) NDA (27) 
GC/NPD 24 Hr (27) 24 Hr (27) 
GC/MS (SCAN) 12 Hr (27) 12 Hr (27) 
GC/MS (SIMS) 24 Hr (27) 24 Hr (27) 
aNDA = No detectable amount. 
Time and ease of use 
Plasma (mls) 
#17 #18 
NDA3 (6) NDA (6) 
NDA (4) NDA (4) 
5 Min (2) 5 Min (2) 
5 Min (2) 5 Min (2) 
10 Min (2) 30 Min (2) 
Detection Limit 
1.0 µg 
0.5 µg 
2.0ng 
10 ng 
2.0ng 
All classical chromatographic techniques for screening and confirmation of analyte 
presence in biological samples require extraction of drug from sample, possibly 
followed by several cleanup steps prior to injection into chromatograph. These 
extraction steps are somewhat cumbersome, taking several hours from start to finish. 
When analyzing a large number of samples by thin-layer chromatography, laboratory 
personnel may spend an entire day extracting and plating samples for screening 
purposes. The add hydrolysis procedure for fentanyl (McDonald and Ozog, 1978) 
entails rather laborious extraction steps, which may take an entire day or two to 
perform. Most sophisticated chromatographic instrumentation such as GC/ NPD and 
GC/ MS require some degree of training in order to fully operate the instrument to its 
capacity. The sophisticated instrumentation, however, allows for automation of a 
large number of samples in a single automation run. 
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SUMMARY 
The purpose of this study was to determine the relative merits between the 
immunochemical techniques, and to compare the relative sensitivity of classical 
detection to immunoassay and instrumental methods in the screening and 
confirmation of fentanyl, in equine urine and plasma. It is already known within the 
forensic racing community that gas chromatography I mass spectrometry is superior to 
the classical screening techniques as well as the new immunoassay methods in the 
overall confirmation of fentanyl in biological samples. 
Of all the commercially available immunochemical assays analyzed, the IDS PCFIA 
assay attained the lowest sensitivity limit and lowest threshold value at < 1.0 pg and 80 
pg total fentanyl, respectively. The IDS ELISA had a sensitivity limit and threshold 
va lue of 1.5 and 100 pg total fentanyl , respectively, approaching those values seen with 
the IDS PCFIA. Thus, on an overall sensitivity standpoint, the IDS PCFIA and IDS 
ELISA are extremely sensitive, with the PCFIA being more sensitive to the parent 
fentanyl molecule. 
All the immunoassay methodologies investigated had good intra-assay 
reproducibility with standards and administration samples. The Janssen 3H RlA was 
indicated as being superior in terms of inter-assay (overall day-to-day) reproducibility 
of results among the immunochemical methods examined . However, the major 
drawback of radioimmunoassays include the prospect of handling radioactive material, 
as well as their rather laborious execution, long time to completion, and low 
sensitivity levels in comparison to the ELISA and PCFIA procedures. 
In terms of administration samples, the IDS ELISA detected presence of fentanyl 
equivalents at the farthest time post administration in both urine and plasma. The 
assay produced positive responses as far out as 24 hour and 1 hour post administration 
for urine and plasma, respectively. The IDS PCFIA methodology also detected fentanyl 
equivalents up to 24 hours post administration in urine, but only detected fentanyl 
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equivalents in plasma up to 5 minutes post administration, possibly due to 
endogenous flu orescent materials in equine plasma. 
A major factor in selecting an immunochemical technique for the detection of 
exogenous compounds in the forensic chemistry community is time to completion of 
an assay. lf large numbers of samples must be analyzed in a rapid fashion on a daily 
basis, assays allowing for these considerations must be utilized in the testing process. 
The IDS PCFIA is extremely rapid, requiring approximately 30 minutes to complete the 
assay and generate results with minimal intra-assay variability. 
Among the classical screening techniques analyzed, the lowest detection limit of 2.0 
ng on column, was accomplished by gas chromatography with nitrogen-phosphorus 
thermionic detection. The sensitivity of the IDS PCFIA is approximately 1000X greater 
in relation to the GC/NPD technique. The results generated by the classical screening 
methods on the administration urine and plasma, did not indicate fentanyl 
administration at a farther time post dose in relation to the immunoassay techniques. 
The optimum laboratory practice for the screening and confirmation of biological 
samples would include initial screening by commercially available immunoassays, 
PCFIA preferably if available. Immunoassay methods are faster, have increased 
sensitivities, and require little instrumentation in comparison to the classical 
screening procedures (TLC, GC/ NPD). When samples are deemed suspicious by 
immunoassay, samples could then be analyzed in triplicate by immunoassay to insure 
the initial positive response was not an anomaly. Lastly, gas chromatography /mass 
spectrometry as a confirmatory tool is a must for legal records and legal identification 
of analyte presence within a sample. 
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SUGGESTIONS FOR FUTURE WORK 
Future work could include investigating and comparing cross-reactivity of the 
commercially available immunochemical techniques to fentanyl analogs and fentanyl-
like compounds. It would be of interest to know which of the various 
immunochemical techniques reacts best with the various fentanyl-like narcotic 
analgesics, such as alfentanil, sufentanil, carfentanil, lofentanil, etc., as many of these 
fentanyl analogs are more potent than fentanyl itself in their pharmacological 
response. 
Attainment and purification of equine fentanyl or fentanyl analog metabolites, 
either through dosing or chemical synthesis, would allow for the study of individual 
metabolite responses with immunochemical assays of interest. It could then be 
determined which metabolites respond to the commercially available immunoassays, 
and which ones do not. 
In addition, administered urines and plasma (equine) could be analyzed with daily 
laboratory procedures to determine how well or poorly the routine screening practices, 
those performed on a day-to~ay basis, can ascertain the presence of fentanyl 
equivalents in the samples. 
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APPENDIX 
Revision of Janssen 3H RIA 
Reagents Supplied in Kit 
3H-labelled fentanyl (1.1 µCi/vial) 
Standard fentanyl (2.0 µg/ml) 
Fentanyl antiserum 
Dextran-charcoal Mixture 
Phosphate buffer-BSA mixture 
Materials Not Supplied 
Distilled water 
Methanol/ distilled water (30:70, v Iv) 
1.5 ml microcentrifuge tubes 
20 ml disposable scintillation vials 
Scintillation cocktail 
Preparation of Reagents 
3H-fentanyl-
Dilu te stock solution with 4.0 ml methanol/ distilled (30:70, v / v) to obtain a 
solution corresponding to 25,000 dpm/50 µl. 
Fentanyl s tandards-
Dilute fentanyl standard solution (2.0 µg / ml) with methanol/ distilled water 
(30:70, v /v) to acquire desired concentrations. 
Fentanyl antiserum-
Reconstitute contents of vial with 20 ml distilled wa ter and mix thoroughly. 
Dextran-charcoal mixture-
Add 25 ml distilled water to dry dextran-charcoal mixture to obtain a 2% 
dextran-coa ted charcoal suspension. 
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Phosphate buffer- BSA mixture-
Dissolve vial contents into 50 ml distilled water to obtain a 0.05 M buffer 
solution at pH 7.5, containing 2% albumin. 
Procedure 
1. Prior to performing the assay, allow all reagents to reach room temperature. 
2. Ultrasonicate samples for 5 minutes prior to use. 
3. Pipet the following into 1.5 ml microcentrifuge tubes (volumes given in µls): 
Sam12Ies Standards Zero Standard NSB TC 
3H-Fentanyl 50 50 50 50 so 
30% MeOH/water 50 NA1 50 50 50 
Fentanyl Standards NA 50 NA NA NA 
Sample 50 NA NA NA N A 
PBS 450 450 500 500 500 
Fentanyl antiserum 200 200 200 NA NA 
Distilled water NA NA NA 200 200 
4. Mix the contents of the tubes and incubate for 2 hours at room temperature 
under continuous rotation (25 rpm). 
5. Add the following: 
Dextran-charcoal 200 200 200 200 NA 
PBS NA NA NA NA 200 
6. Mix the contents of the tubes and incubate for 1 hour at room temperature 
under continous rotation (25 rpm). 
7. Centrifuge the tubes at 8000 x g for 5-10 minutes. 
8. Pipet the total supernatant into counting vials with 10 mls scintillation cocktail 
and determine the "total tritium activity" of the vials by scintillation counter. 
9. Convert "total activity" (counts) to %B/B0 and interpret results. 
1 NA = No addition. 
I I 0 
Cambridge Medical 125J-RIA 
Reagents Supplied in Kit 
125J-labelled fentanyl (1.0 µCi/vial) 
Standard fentanyl (2.0 µg/ml) 
Fentanyl antiserum 
Precipitating reagent 
Fentanyl assay buffer 
Normal rabbit serum 
Materials Not Supplied 
1.5 ml microcentrifuge tubes 
20 ml disposable scintilla ti on vials 
Scintillation cocktail 
Preparation of Rea&ents 
Normal rabbit serum-
Reconstitute with 11.0 ml assay buffer. 
125J-fentanyl-
Dilute vial with 11.0 ml of normal rabbit serum. Recap and swirl contents. 
Fentanyl Standards-
Dilute fentanyl standard solution (2.0 µg / ml) with assay buffer to acquire 
desired concentrations. 
Assay buffer-
Ready to use. 
Fentanyl Antiserum-
Read y to use. 
Precipitating Reagent-
Ready to use. 
I I I 
Procedure 
1. Prior to performing the assay, allow all reagents to reach room temperature. 
Ultrasonicate samples for 5 minutes prior to use. 2. 
3. Pipet the following into 1.5 ml microcentrifuge tubes (volumes given in µls): 
Sam12les Standards Zero Standard NSBl TC2 
Assay Buffer NA3 NA 100 NA NA 
Fentanyl Standards NA 100 NA NA NA 
Samples 100 NA NA NA NA 
125J-Fentanyl 100 100 100 100 100 
Fentanyl antiserum 200 200 200 NA NA 
4. Vortex gently and incubate for 90 minutes at room temperature. 
5. Add the following: 
Precipitating reagent 1000 1000 1000 1000 NA 
6. Vortex and incubate at room temperature for 15 minutes . 
7. Centrifuge the tubes at 1500 x g for 5-10 minutes. 
8. Pipet 100 µl of supernatant into counting vials with 10 mls scintillation cocktail 
and determine the "total tritium activity" of the vials via a scintillation 
counter. 
9. Convert "total activity" (counts) to %B/ B0 and interpret results . 
1 NSB = Non-specific binding. 
2TC =Total counts. 
3NA = No addition. 
1 1 2 
IDS ELISA 
Materials Supplied in Kit 
Fentanyl microtitre strips (coated with antibody) and Holder 
Substrate solution A and B 
Fentanyl-enzyme conjugate 
Enzyme diluent 
ELISA wash solution (10X) 
ELISA standard and sample diluent 
Rea gents Not Supplied 
Fentanyl standard at 1 µg / µl (methanol) 
Distilled water 
Procedure 
1. Prior to performing the assay, allow all reagents to reach room temperature. 
2. Ultrasonicate samples for 5 minutes prior to use. 
3. Add 20 µl of standard and/or sample extracts to appropriate wells of microtitre 
strips. 
4. All 100 µl of enzyme solution (prepared by a 1 :8000 dilution with diluent) to each 
well, and gently mix by shaking. 
5. Let reaction proceed at room temperature for 30 minutes. 
6. Dump wells and wash three times with wash solution (diluted 1:10 with distilled 
water), ensuring that the wells are overflowed with wash solution each time. 
7. Tamp dry and remove the presence of any bubbles in the wells. 
8. Add 150 µl of substrate to each well (substrate is made by mixing equal amounts 
of solution A and B). 
9. Allow reaction to proceed at room temperature for 30 minutes. 
10. Read optical density (absorbance) of each well at 650 nm, and interpret results. 
1 1 3 
Tri-Tee ELISA 
Materials Supplied in Kit 
1. One microtitre plate (coated with fentanyl antigen) 
2. One vial HRP-Antibody to fentanyl (rabbit) 
3. Two vials substrate buffer for OPD (o-phenylenediamine) containing hydrogen 
peroxide 
4. One vial (2 tablets) OPD tablets (5 mg) 
5. One vial stop solution 
6. 100 ml wash concentrate containing phospho-buffered saline with Tween 20 
7. Fentanyl Urine Standards-
1.0 ng /ml, 2.0 ng /ml, 4.0 ng/ml, 10.0 ng/ ml, and 20.0 ng/ml 
Reagents Not Supplied 
Distilled water 
Procedure 
1. Prior to performing the assay, allow all reagents to reach room temperature . 
2. Ultrasonicate samples for 5 minutes prior to use. 
3. Add 50 µl of standard/sample extracts to appropriate wells of microtitre plate. 
4. Add 50 µI /well of fentanyl conjugate solution. 
5. Shake gently to mix and let reaction proceed at room tempera ture for one hour. 
6. At approximately 10 minutes prior to end of incubation period, prepare 
substrate. To 30 or 60 mls of substrate buffer, add 1 OPD tablet. 
7. Dump wells and wash three times with wash solution (diluted 1 :10 with distilled 
water), ensuring that the wells are overflowed with wash solution each time. 
8. Tamp dry and remove the presence of any bubbles in the wells. 
9. Add 200 µI of substrate to each well. 
10. Allow reaction to proceed at room temperature for 15 minutes. 
11 . Stop reaction by adding 50 µI of stop solution to each well. 
12. Read optical density (absorbance) of each well at 490 nm, and interpret results. 
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IDS PCFIA 
Reagents Supplied in Kit 
Fentanyl-BPE (beta-phycoerythrin) reagent 
Fentanyl antibody reagent 
Fentanyl latex particles (goat anti-rabbit) reagent 
Wash solution (lOX) 
PCFIA standard and sample diluent 
Reagents Not Supplied 
Fentanyl standard at 1 µg/µl (methanol) 
Distilled water 
Procedure 
1. Prior to performing the assay, allow all reagents to reach room temperature. 
2. Ultrasonicate samples for 5 minutes prior to use. 
3. Spin filter all urine samples for 5 minutes at 10,000 x g in Spin-X™ filters. 
4. Add 20 µI of standard and/ or sample extracts to appropriate wells in the ninety-
six well vacuum filtration microtitre plate. 
5. Add 20 µI of the drug-phycoerythrin conjugate to each well . 
6. Add 20 µI of drug antisera to each well. 
7. Allow the reaction to proceed at room temperature for 10 minutes. 
8. Add 20 µl of latex particles to each microtiter well. 
9. Gently mix by tapping the microtiter plate and allow reaction to proceed at room 
temperature for 10 minutes. 
10. To all empty wells, add 20 µI distilled water. 
11 . Place plate in Fluorescence Concentration Analyzer (FCA) and vacuum filter 
plate at 20 mm Hg until all wells are completely aspirated. 
12. Wash plate one time with wash solution (diluted 1:10 with distilled water). 
13. When wells are completely dry, read fluorescence at an excitation/ emission 
wavelength of 545/ 575 nm and interpret results. 
1 1 5 
Iodoplatinate Reagent 
Ingredients 
10% chloroplatinic acid solution (3 ml) 
97 mls water 
Aqueous 6% KI solution (100 ml) 
Procedure 
1. Add 3 mls 10% chloroplatinic acid to 97 mls water. 
2. Add 100 mls aqueous 6% Kl solution and mix. 
